Search

Your search keyword '"Malats N."' showing total 782 results
Start Over Author "Malats N."
782 results on '"Malats N."'

101. Recurrence and progression according to stage at re-TUR in t1g3 bladder cancer patients treated with BCG: Not as bad as previously thought

Author

Palou, J., primary, Gontero, P., additional, Pisano, F., additional, Joniau, S., additional, Oderda, M., additional, Serretta, V., additional, Larrè, S., additional, Di Stasi, S., additional, Van Rhijn, B., additional, Witjes, A.J., additional, Grotenhuis, A.J., additional, Colombo, R., additional, Briganti, A., additional, Babjuk, M., additional, Soukup, V., additional, Malmstrom, P.U., additional, Irani, J., additional, Malats, N., additional, Baniel, J., additional, Mano, R., additional, Cai, T., additional, Cha, E.K., additional, Ardelt, P., additional, Varkarakis, J., additional, Bartoletti, R., additional, Dalbagni, G., additional, Shariat, S., additional, Xylinas, E., additional, Karnes, R.J., additional, and Sylvester, R., additional

Published
2017
Full Text
View/download PDF

102. The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high/grade/Grade 3 bladder cancer treated with bacillus Calmette Guerin

Author

Gontero, P, Sylvester, R, Pisano, F, Joniau, S, Oderda, M, Serretta, V, Larré, S, Di Stasi, S, Van Rhijn, B, Witjes, Aj, Grotenhuis, Aj, Colombo, R, Briganti, A, Babjuk, M, Soukup, V, Malmström, Pu, Irani, J, Malats, N, Baniel, J, Mano, R, Cai, T, Cha, Ek, Ardelt, P, Vakarakis, J, Bartoletti, Riccardo, Dalbagni, G, Shariat, Sf, Xylinas, E, Karnes, Rj, and Palou, J.

Subjects
recurrence, re-TUR, bladder cancer, T1G3, progression, bladder cancer, T1G3, high grade, re-TUR, recurrence, progression, high grade
Published
2015

103. Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with bacillus calmette-guérin: Results of a retrospective multicenter study of 2451 patients

Author

Gontero, P. Sylvester, R. Pisano, F. Joniau, S. Vander Eeckt, K. Serretta, V. Larré, S. Di Stasi, S. Van Rhijn, B. Witjes, A.J. Grotenhuis, A.J. Kiemeney, L.A. Colombo, R. Briganti, A. Babjuk, M. Malmström, P.-U. Oderda, M. Irani, J. Malats, N. Baniel, J. Mano, R. Cai, T. Cha, E.K. Ardelt, P. Varkarakis, J. Bartoletti, R. Spahn, M. Johansson, R. Frea, B. Soukup, V. Xylinas, E. Dalbagni, G. Karnes, R.J. Shariat, S.F. Palou, J.

Abstract

Background The impact of prognostic factors in T1G3 non-muscle-invasive bladder cancer (BCa) patients is critical for proper treatment decision making. Objective To assess prognostic factors in patients who received bacillus Calmette-Guérin (BCG) as initial intravesical treatment of T1G3 tumors and to identify a subgroup of high-risk patients who should be considered for more aggressive treatment. Design, setting, and participants Individual patient data were collected for 2451 T1G3 patients from 23 centers who received BCG between 1990 and 2011. Outcome measurements and statistical analysis Using Cox multivariable regression, the prognostic importance of several clinical variables was assessed for time to recurrence, progression, BCa-specific survival, and overall survival (OS). Results and limitations With a median follow-up of 5.2 yr, 465 patients (19%) progressed, 509 (21%) underwent cystectomy, and 221 (9%) died because of BCa. In multivariable analyses, the most important prognostic factors for progression were age, tumor size, and concomitant carcinoma in situ (CIS); the most important prognostic factors for BCa-specific survival and OS were age and tumor size. Patients were divided into four risk groups for progression according to the number of adverse factors among age ≥70 yr, size ≥3 cm, and presence of CIS. Progression rates at 10 yr ranged from 17% to 52%. BCa-specific death rates at 10 yr were 32% in patients ≥70 yr with tumor size ≥3 cm and 13% otherwise. Conclusions T1G3 patients ≥70 yr with tumors ≥3 cm and concomitant CIS should be treated more aggressively because of the high risk of progression. Patient summary Although the majority of T1G3 patients can be safely treated with intravesical bacillus Calmette-Guérin, there is a subgroup of T1G3 patients with age ≥70 yr, tumor size ≥3 cm, and concomitant CIS who have a high risk of progression and thus require aggressive treatment. © 2014 European Association of Urology.

Published
2015

104. The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer treated with bacille Calmette-Guerin

Author

Gontero, P., Sylvester, R., Pisano, F., Joniau, S., Oderda, M., Serretta, V., Larre, S., Stasi, S. Di, Rhijn, B. Van, Witjes, A.J., Grotenhuis, A.J., Colombo, R., Briganti, A., Babjuk, M., Soukup, V., Malmstrom, P.U., Irani, J., Malats, N., Baniel, J., Mano, R., Cai, T., Cha, E.K., Ardelt, P., Vakarakis, J., Bartoletti, R., Dalbagni, G., Shariat, S.F., Xylinas, E., Karnes, R.J., Palou, J., Gontero, P., Sylvester, R., Pisano, F., Joniau, S., Oderda, M., Serretta, V., Larre, S., Stasi, S. Di, Rhijn, B. Van, Witjes, A.J., Grotenhuis, A.J., Colombo, R., Briganti, A., Babjuk, M., Soukup, V., Malmstrom, P.U., Irani, J., Malats, N., Baniel, J., Mano, R., Cai, T., Cha, E.K., Ardelt, P., Vakarakis, J., Bartoletti, R., Dalbagni, G., Shariat, S.F., Xylinas, E., Karnes, R.J., and Palou, J.

Abstract

Item does not contain fulltext, OBJECTIVES: To determine if a re-transurethral resection (TUR), in the presence or absence of muscle at the first TUR in patients with T1-high grade (HG)/Grade 3 (G3) bladder cancer, makes a difference in recurrence, progression, cancer specific (CSS) and overall survival (OS). PATIENTS AND METHODS: In a large retrospective multicentre cohort of 2451 patients with T1-HG/G3 initially treated with bacille Calmette-Guerin, 935 (38%) had a re-TUR. According to the presence or absence of muscle in the specimen of the primary TUR, patients were divided in four groups: group 1 (no muscle, no re-TUR), group 2 (no muscle, re-TUR), group 3 (muscle, no re-TUR) and group 4 (muscle, re-TUR). Clinical outcomes were compared across the four groups. RESULTS: Re-TUR had a positive impact on recurrence, progression, CSS and OS only if muscle was not present in the primary TUR specimen. Adjusting for the most important prognostic factors, re-TUR in the absence of muscle had a borderline significant effect on time to recurrence [hazard ratio (HR) 0.67, P = 0.08], progression (HR 0.46, P = 0.06), CSS (HR 0.31, P = 0.07) and OS (HR 0.48, P = 0.05). Re-TUR in the presence of muscle in the primary TUR specimen did not improve the outcome for any of the endpoints. CONCLUSIONS: Our retrospective analysis suggests that re-TUR may not be necessary in patients with T1-HG/G3, if muscle is present in the specimen of the primary TUR.

Published
2016

105. The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non-muscle-invasive bladder cancer

Author

Witjes, J.A., Dalbagni, G., Karnes, R.J., Shariat, S., Joniau, S., Palou, J., Serretta, V., Larre, S., Stasi, S. Di, Colombo, R., Babjuk, M., Malmstrom, P.U., Malats, N., Irani, J., Baniel, J., Cai, T., Cha, E., Ardelt, P., Varkarakis, J., Bartoletti, R., Spahn, M., Pisano, F., Gontero, P., Sylvester, R., Witjes, J.A., Dalbagni, G., Karnes, R.J., Shariat, S., Joniau, S., Palou, J., Serretta, V., Larre, S., Stasi, S. Di, Colombo, R., Babjuk, M., Malmstrom, P.U., Malats, N., Irani, J., Baniel, J., Cai, T., Cha, E., Ardelt, P., Varkarakis, J., Bartoletti, R., Spahn, M., Pisano, F., Gontero, P., and Sylvester, R.

Abstract

Item does not contain fulltext, BACKGROUND: Potential differences in efficacy of different bacillus Calmette-Guerin (BCG) strains are of importance for daily practice, especially in the era of BCG shortage. OBJECTIVE: To retrospectively compare the outcome with BCG Connaught and BCG TICE in a large study cohort of pT1 high-grade non-muscle-invasive bladder cancer patients. DESIGN, SETTING, AND PARTICIPANTS: Individual patient data were collected for 2,451 patients with primary T1G3 tumors from 23 centers who were treated with BCG for the first time between 1990 and 2011. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Using Cox multivariable regression and adjusting for the most important prognostic factors in this nonrandomized comparison, BCG Connaught and TICE were compared for time to recurrence, progression, and the duration of cancer specific survival and overall survival. RESULTS AND LIMITATIONS: Information on the BCG strain was available for 2,099 patients: 957 on Connaught and 1,142 on TICE. Overall, 765 (36%) patients received some form of maintenance BCG, 560 (59%) on Connaught and 205 (18%) on TICE. Without maintenance, Connaught was more effective than TICE only for the time to first recurrence (hazard ratio [HR] = 1.48; 95% CI: 1.20-1.82; P<0.001). With maintenance, TICE was more effective than Connaught for the time to first recurrence (HR = 0.66; 95% CI: 0.47-0.93; P = 0.019) with a trend for cancer specific survival (HR = 0.36; 95% CI: 0.14-0.92; P = 0.033). For time to progression and overall survival, Connaught and TICE had a similar efficacy. Compared to no maintenance therapy, maintenance BCG significantly reduced the risk of recurrence, progression and death, both overall, and disease specific, for TICE, but not for Connaught. CONCLUSIONS: We found that BCG Connaught results in a lower recurrence rate as compared with BCG TICE when no maintenance is used. However, the opposite is true when maintenance is given. PATIENT SUMMARY: As there is currently a BCG shortage, informatio

Published
2016

106. Identification of a novel susceptibility locus at 13q34 and refinement of the 20p12.2 region as a multi-signal locus associated with bladder cancer risk in individuals of European ancestry

Author

Figueroa, J.D., Middlebrooks, C.D., Banday, A.R., Ye, Y., Garcia-Closas, M., Chatterjee, N., Koutros, S., Kiemeney, L.A., Rafnar, T., Bishop, T., Furberg, H., Matullo, G., Golka, K., Gago-Dominguez, M., Taylor, J.A., Fletcher, T., Siddiq, A., Cortessis, V.K., Kooperberg, C., Cussenot, O., Benhamou, S., Prescott, J., Porru, S., Dinney, C.P., Malats, N., Baris, D., Purdue, M.P., Jacobs, E.J., Albanes, D., Wang, Z., Chung, C.C., Vermeulen, S.H., Aben, K.K.H., Galesloot, T.E., Thorleifsson, G., Sulem, P., Stefansson, K., Kiltie, A.E., Harland, M., Teo, M., Offit, K., Vijai, J., Bajorin, D., Kopp, R., Fiorito, G., Guarrera, S., Sacerdote, C., Selinski, S., Hengstler, J.G., Gerullis, H., Ovsiannikov, D., Blaszkewicz, M., Castelao, J.E., Calaza, M., Martinez, M.E., Cordeiro, P., Xu, Z., Panduri, V., Kumar, R., Gurzau, E, Koppova, K., Bueno-de-Mesquita, H.B., Ljungberg, B., Clavel-Chapelon, F., Weiderpass, E., Krogh, V., Dorronsoro, M., Travis, R.C., Tjonneland, A., Brennan, P., Chang-Claude, J., Riboli, E., Conti, D., Stern, M.C., Pike, M.C., Berg, D., Yuan, J.M., Hohensee, C., Jeppson, R.P., Cancel-Tassin, G., Roupret, M., Comperat, E., Turman, C., Vivo, I. De, Giovannucci, E., Hunter, D.J., Kraft, P., Lindstrom, S., Carta, A., Pavanello, S., Arici, C., Mastrangelo, G., Kamat, A.M., Zhang, L., Gong, Y., Pu, X., Hutchinson, A., Burdett, L., Wheeler, W.A., Karagas, M.R., et al., Figueroa, J.D., Middlebrooks, C.D., Banday, A.R., Ye, Y., Garcia-Closas, M., Chatterjee, N., Koutros, S., Kiemeney, L.A., Rafnar, T., Bishop, T., Furberg, H., Matullo, G., Golka, K., Gago-Dominguez, M., Taylor, J.A., Fletcher, T., Siddiq, A., Cortessis, V.K., Kooperberg, C., Cussenot, O., Benhamou, S., Prescott, J., Porru, S., Dinney, C.P., Malats, N., Baris, D., Purdue, M.P., Jacobs, E.J., Albanes, D., Wang, Z., Chung, C.C., Vermeulen, S.H., Aben, K.K.H., Galesloot, T.E., Thorleifsson, G., Sulem, P., Stefansson, K., Kiltie, A.E., Harland, M., Teo, M., Offit, K., Vijai, J., Bajorin, D., Kopp, R., Fiorito, G., Guarrera, S., Sacerdote, C., Selinski, S., Hengstler, J.G., Gerullis, H., Ovsiannikov, D., Blaszkewicz, M., Castelao, J.E., Calaza, M., Martinez, M.E., Cordeiro, P., Xu, Z., Panduri, V., Kumar, R., Gurzau, E, Koppova, K., Bueno-de-Mesquita, H.B., Ljungberg, B., Clavel-Chapelon, F., Weiderpass, E., Krogh, V., Dorronsoro, M., Travis, R.C., Tjonneland, A., Brennan, P., Chang-Claude, J., Riboli, E., Conti, D., Stern, M.C., Pike, M.C., Berg, D., Yuan, J.M., Hohensee, C., Jeppson, R.P., Cancel-Tassin, G., Roupret, M., Comperat, E., Turman, C., Vivo, I. De, Giovannucci, E., Hunter, D.J., Kraft, P., Lindstrom, S., Carta, A., Pavanello, S., Arici, C., Mastrangelo, G., Kamat, A.M., Zhang, L., Gong, Y., Pu, X., Hutchinson, A., Burdett, L., Wheeler, W.A., Karagas, M.R., and et al.

Abstract

Contains fulltext : 167299.pdf (publisher's version ) (Closed access), Candidate gene and genome-wide association studies (GWAS) have identified 15 independent genomic regions associated with bladder cancer risk. In search for additional susceptibility variants, we followed up on four promising single-nucleotide polymorphisms (SNPs) that had not achieved genome-wide significance in 6911 cases and 11 814 controls (rs6104690, rs4510656, rs5003154 and rs4907479, P < 1 x 10(-6)), using additional data from existing GWAS datasets and targeted genotyping for studies that did not have GWAS data. In a combined analysis, which included data on up to 15 058 cases and 286 270 controls, two SNPs achieved genome-wide statistical significance: rs6104690 in a gene desert at 20p12.2 (P = 2.19 x 10(-11)) and rs4907479 within the MCF2L gene at 13q34 (P = 3.3 x 10(-10)). Imputation and fine-mapping analyses were performed in these two regions for a subset of 5551 bladder cancer cases and 10 242 controls. Analyses at the 13q34 region suggest a single signal marked by rs4907479. In contrast, we detected two signals in the 20p12.2 region-the first signal is marked by rs6104690, and the second signal is marked by two moderately correlated SNPs (r(2) = 0.53), rs6108803 and the previously reported rs62185668. The second 20p12.2 signal is more strongly associated with the risk of muscle-invasive (T2-T4 stage) compared with non-muscle-invasive (Ta, T1 stage) bladder cancer (case-case P

Published
2016

107. Prediction of non-muscle invasive bladder cancer outcomes assessed by innovative multimarker prognostic models

Author

Lopez de Maturana, E, Picornell, A, Masson-Lecomte, A, Kogevinas, M, Marquez, M, Carrato, A, Tardon, A, Lloreta, J, Garcia-Closas, M, Silverman, D, Rothman, N, Chanock, S, Real, FX, Goddard, ME, Malats, N, Lopez de Maturana, E, Picornell, A, Masson-Lecomte, A, Kogevinas, M, Marquez, M, Carrato, A, Tardon, A, Lloreta, J, Garcia-Closas, M, Silverman, D, Rothman, N, Chanock, S, Real, FX, Goddard, ME, and Malats, N

Abstract

BACKGROUND: We adapted Bayesian statistical learning strategies to the prognosis field to investigate if genome-wide common SNP improve the prediction ability of clinico-pathological prognosticators and applied it to non-muscle invasive bladder cancer (NMIBC) patients. METHODS: Adapted Bayesian sequential threshold models in combination with LASSO were applied to consider the time-to-event and the censoring nature of data. We studied 822 NMIBC patients followed-up >10 years. The study outcomes were time-to-first-recurrence and time-to-progression. The predictive ability of the models including up to 171,304 SNP and/or 6 clinico-pathological prognosticators was evaluated using AUC-ROC and determination coefficient. RESULTS: Clinico-pathological prognosticators explained a larger proportion of the time-to-first-recurrence (3.1 %) and time-to-progression (5.4 %) phenotypic variances than SNPs (1 and 0.01 %, respectively). Adding SNPs to the clinico-pathological-parameters model slightly improved the prediction of time-to-first-recurrence (up to 4 %). The prediction of time-to-progression using both clinico-pathological prognosticators and SNP did not improve. Heritability (ĥ (2)) of both outcomes was <1 % in NMIBC. CONCLUSIONS: We adapted a Bayesian statistical learning method to deal with a large number of parameters in prognostic studies. Common SNPs showed a limited role in predicting NMIBC outcomes yielding a very low heritability for both outcomes. We report for the first time a heritability estimate for a disease outcome. Our method can be extended to other disease models.

Published
2016

108. Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21

Author

Zhang, M, Wang, Z, Obazee, O, Jia, J, Childs, EJ, Hoskins, J, Figlioli, G, Mocci, E, Collins, I, Chung, CC, Hautman, C, Arslan, AA, Beane-Freeman, L, Bracci, PM, Buring, J, Duell, EJ, Gallinger, S, Giles, GG, Goodman, GE, Goodman, PJ, Kamineni, A, Kolonel, LN, Kulke, MH, Malats, N, Olson, SH, Sesso, HD, Visvanathan, K, White, E, Zheng, W, Abnet, CC, Albanes, D, Andreotti, G, Brais, L, Bueno-de-Mesquita, HB, Basso, D, Berndt, SI, Boutron-Ruault, M-C, Bijlsma, MF, Brenner, H, Burdette, L, Campa, D, Caporaso, NE, Capurso, G, Cavestro, GM, Cotterchio, M, Costello, E, Elena, J, Boggi, U, Gaziano, JM, Gazouli, M, Giovannucci, EL, Goggins, M, Gross, M, Haiman, CA, Hassan, M, Helzlsouer, KJ, Hu, N, Hunter, DJ, Iskierka-Jazdzewska, E, Jenab, M, Kaaks, R, Key, TJ, Khaw, K-T, Klein, EA, Kogevinas, M, Krogh, V, Kupcinskas, J, Kurtz, RC, Landi, MT, Landi, S, Le Marchand, L, Mambrini, A, Mannisto, S, Milne, RL, Neale, RE, Oberg, AL, Panico, S, Patel, AV, Peeters, PHM, Peters, U, Pezzilli, R, Porta, M, Purdue, M, Ramon Quiros, J, Riboli, E, Rothman, N, Scarpa, A, Scelo, G, Shu, X-O, Silverman, DT, Soucek, P, Strobel, O, Sund, M, Malecka-Panas, E, Taylor, PR, Tavano, F, Travis, RC, Thornquist, M, Tjonneland, A, Tobias, GS, Trichopoulos, D, Vashist, Y, Vodicka, P, Wactawski-Wende, J, Wentzensen, N, Yu, H, Yu, K, Zeleniuch-Jacquotte, A, Kooperberg, C, Risch, HA, Jacobs, EJ, Li, D, Fuchs, C, Hoover, R, Hartge, P, Chanock, SJ, Petersen, GM, Stolzenberg-Solomon, RS, Wolpin, BM, Kraft, P, Klein, AP, Canzian, F, Amundadottir, LT, Zhang, M, Wang, Z, Obazee, O, Jia, J, Childs, EJ, Hoskins, J, Figlioli, G, Mocci, E, Collins, I, Chung, CC, Hautman, C, Arslan, AA, Beane-Freeman, L, Bracci, PM, Buring, J, Duell, EJ, Gallinger, S, Giles, GG, Goodman, GE, Goodman, PJ, Kamineni, A, Kolonel, LN, Kulke, MH, Malats, N, Olson, SH, Sesso, HD, Visvanathan, K, White, E, Zheng, W, Abnet, CC, Albanes, D, Andreotti, G, Brais, L, Bueno-de-Mesquita, HB, Basso, D, Berndt, SI, Boutron-Ruault, M-C, Bijlsma, MF, Brenner, H, Burdette, L, Campa, D, Caporaso, NE, Capurso, G, Cavestro, GM, Cotterchio, M, Costello, E, Elena, J, Boggi, U, Gaziano, JM, Gazouli, M, Giovannucci, EL, Goggins, M, Gross, M, Haiman, CA, Hassan, M, Helzlsouer, KJ, Hu, N, Hunter, DJ, Iskierka-Jazdzewska, E, Jenab, M, Kaaks, R, Key, TJ, Khaw, K-T, Klein, EA, Kogevinas, M, Krogh, V, Kupcinskas, J, Kurtz, RC, Landi, MT, Landi, S, Le Marchand, L, Mambrini, A, Mannisto, S, Milne, RL, Neale, RE, Oberg, AL, Panico, S, Patel, AV, Peeters, PHM, Peters, U, Pezzilli, R, Porta, M, Purdue, M, Ramon Quiros, J, Riboli, E, Rothman, N, Scarpa, A, Scelo, G, Shu, X-O, Silverman, DT, Soucek, P, Strobel, O, Sund, M, Malecka-Panas, E, Taylor, PR, Tavano, F, Travis, RC, Thornquist, M, Tjonneland, A, Tobias, GS, Trichopoulos, D, Vashist, Y, Vodicka, P, Wactawski-Wende, J, Wentzensen, N, Yu, H, Yu, K, Zeleniuch-Jacquotte, A, Kooperberg, C, Risch, HA, Jacobs, EJ, Li, D, Fuchs, C, Hoover, R, Hartge, P, Chanock, SJ, Petersen, GM, Stolzenberg-Solomon, RS, Wolpin, BM, Kraft, P, Klein, AP, Canzian, F, and Amundadottir, LT

Abstract

Genome-wide association studies (GWAS) have identified common pancreatic cancer susceptibility variants at 13 chromosomal loci in individuals of European descent. To identify new susceptibility variants, we performed imputation based on 1000 Genomes (1000G) Project data and association analysis using 5,107 case and 8,845 control subjects from 27 cohort and case-control studies that participated in the PanScan I-III GWAS. This analysis, in combination with a two-staged replication in an additional 6,076 case and 7,555 control subjects from the PANcreatic Disease ReseArch (PANDoRA) and Pancreatic Cancer Case-Control (PanC4) Consortia uncovered 3 new pancreatic cancer risk signals marked by single nucleotide polymorphisms (SNPs) rs2816938 at chromosome 1q32.1 (per allele odds ratio (OR) = 1.20, P = 4.88x10 -15), rs10094872 at 8q24.21 (OR = 1.15, P = 3.22x10 -9) and rs35226131 at 5p15.33 (OR = 0.71, P = 1.70x10 -8). These SNPs represent independent risk variants at previously identified pancreatic cancer risk loci on chr1q32.1 ( NR5A2), chr8q24.21 ( MYC) and chr5p15.33 ( CLPTM1L- TERT) as per analyses conditioned on previously reported susceptibility variants. We assessed expression of candidate genes at the three risk loci in histologically normal ( n = 10) and tumor ( n = 8) derived pancreatic tissue samples and observed a marked reduction of NR5A2 expression (chr1q32.1) in the tumors (fold change -7.6, P = 5.7x10 -8). This finding was validated in a second set of paired ( n = 20) histologically normal and tumor derived pancreatic tissue samples (average fold change for three NR5A2 isoforms -31.3 to -95.7, P = 7.5x10 -4-2.0x10 -3). Our study has identified new susceptibility variants independently conferring pancreatic cancer risk that merit functional follow-up to identify target genes and explain the underlying biology.

Published
2016

109. Female chromosome X mosaicism is age-related and preferentially affects the inactivated X chromosome

Author

Machiela, MJ, Zhou, W, Karlins, E, Sampson, JN, Freedman, ND, Yang, Q, Hicks, B, Dagnall, C, Hautman, C, Jacobs, KB, Abnet, CC, Aldrich, MC, Amos, C, Amundadottir, LT, Arslan, AA, Beane-Freeman, LE, Berndt, SI, Black, A, Blot, WJ, Bock, CH, Bracci, PM, Brinton, LA, Bueno-de-Mesquita, HB, Burdett, L, Buring, JE, Butler, MA, Canzian, F, Carreon, T, Chaffee, KG, Chang, I-S, Chatterjee, N, Chen, C, Chen, K, Chung, CC, Cook, LS, Bou, MC, Cullen, M, Davis, FG, De Vivo, I, Ding, T, Doherty, J, Duell, EJ, Epstein, CG, Fan, J-H, Figueroa, JD, Fraumeni, JF, Friedenreich, CM, Fuchs, CS, Gallinger, S, Gao, Y-T, Gapstur, SM, Garcia-Closas, M, Gaudet, MM, Gaziano, JM, Giles, GG, Gillanders, EM, Giovannucci, EL, Goldin, L, Goldstein, AM, Haiman, CA, Hallmans, G, Hankinson, SE, Harris, CC, Henriksson, R, Holly, EA, Hong, Y-C, Hoover, RN, Hsiung, CA, Hu, N, Hu, W, Hunter, DJ, Hutchinson, A, Jenab, M, Johansen, C, Khaw, K-T, Kim, HN, Kim, YH, Kim, YT, Klein, AP, Klein, R, Koh, W-P, Kolonel, LN, Kooperberg, C, Kraft, P, Krogh, V, Kurtz, RC, LaCroix, A, Lan, Q, Landi, MT, Le Marchand, L, Li, D, Liang, X, Liao, LM, Lin, D, Liu, J, Lissowska, J, Lu, L, Magliocco, AM, Malats, N, Matsuo, K, McNeill, LH, McWilliams, RR, Melin, BS, Mirabello, L, Moore, L, Olson, SH, Orlow, I, Park, JY, Patino-Garcia, A, Peplonska, B, Peters, U, Petersen, GM, Pooler, L, Prescott, J, Prokunina-Olsson, L, Purdue, MP, Qiao, Y-L, Rajaraman, P, Real, FX, Riboli, E, Risch, HA, Rodriguez-Santiago, B, Ruder, AM, Savage, SA, Schumacher, F, Schwartz, AG, Schwartz, KL, Seow, A, Setiawan, VW, Severi, G, Shen, H, Sheng, X, Shin, M-H, Shu, X-O, Silverman, DT, Spitz, MR, Stevens, VL, Stolzenberg-Solomon, R, Stram, D, Tang, Z-Z, Taylor, PR, Teras, LR, Tobias, GS, Van den Berg, D, Visvanathan, K, Wacholder, S, Wang, J-C, Wang, Z, Wentzensen, N, Wheeler, W, White, E, Wiencke, JK, Wolpin, BM, Wong, MP, Wu, C, Wu, T, Wu, X, Wu, Y-L, Wunder, JS, Xia, L, Yang, HP, Yang, P-C, Yu, K, Zanetti, KA, Zeleniuch-Jacquotte, A, Zheng, W, Zhou, B, Ziegler, RG, Perez-Jurado, LA, Caporaso, NE, Rothman, N, Tucker, M, Dean, MC, Yeager, M, Chanock, SJ, Machiela, MJ, Zhou, W, Karlins, E, Sampson, JN, Freedman, ND, Yang, Q, Hicks, B, Dagnall, C, Hautman, C, Jacobs, KB, Abnet, CC, Aldrich, MC, Amos, C, Amundadottir, LT, Arslan, AA, Beane-Freeman, LE, Berndt, SI, Black, A, Blot, WJ, Bock, CH, Bracci, PM, Brinton, LA, Bueno-de-Mesquita, HB, Burdett, L, Buring, JE, Butler, MA, Canzian, F, Carreon, T, Chaffee, KG, Chang, I-S, Chatterjee, N, Chen, C, Chen, K, Chung, CC, Cook, LS, Bou, MC, Cullen, M, Davis, FG, De Vivo, I, Ding, T, Doherty, J, Duell, EJ, Epstein, CG, Fan, J-H, Figueroa, JD, Fraumeni, JF, Friedenreich, CM, Fuchs, CS, Gallinger, S, Gao, Y-T, Gapstur, SM, Garcia-Closas, M, Gaudet, MM, Gaziano, JM, Giles, GG, Gillanders, EM, Giovannucci, EL, Goldin, L, Goldstein, AM, Haiman, CA, Hallmans, G, Hankinson, SE, Harris, CC, Henriksson, R, Holly, EA, Hong, Y-C, Hoover, RN, Hsiung, CA, Hu, N, Hu, W, Hunter, DJ, Hutchinson, A, Jenab, M, Johansen, C, Khaw, K-T, Kim, HN, Kim, YH, Kim, YT, Klein, AP, Klein, R, Koh, W-P, Kolonel, LN, Kooperberg, C, Kraft, P, Krogh, V, Kurtz, RC, LaCroix, A, Lan, Q, Landi, MT, Le Marchand, L, Li, D, Liang, X, Liao, LM, Lin, D, Liu, J, Lissowska, J, Lu, L, Magliocco, AM, Malats, N, Matsuo, K, McNeill, LH, McWilliams, RR, Melin, BS, Mirabello, L, Moore, L, Olson, SH, Orlow, I, Park, JY, Patino-Garcia, A, Peplonska, B, Peters, U, Petersen, GM, Pooler, L, Prescott, J, Prokunina-Olsson, L, Purdue, MP, Qiao, Y-L, Rajaraman, P, Real, FX, Riboli, E, Risch, HA, Rodriguez-Santiago, B, Ruder, AM, Savage, SA, Schumacher, F, Schwartz, AG, Schwartz, KL, Seow, A, Setiawan, VW, Severi, G, Shen, H, Sheng, X, Shin, M-H, Shu, X-O, Silverman, DT, Spitz, MR, Stevens, VL, Stolzenberg-Solomon, R, Stram, D, Tang, Z-Z, Taylor, PR, Teras, LR, Tobias, GS, Van den Berg, D, Visvanathan, K, Wacholder, S, Wang, J-C, Wang, Z, Wentzensen, N, Wheeler, W, White, E, Wiencke, JK, Wolpin, BM, Wong, MP, Wu, C, Wu, T, Wu, X, Wu, Y-L, Wunder, JS, Xia, L, Yang, HP, Yang, P-C, Yu, K, Zanetti, KA, Zeleniuch-Jacquotte, A, Zheng, W, Zhou, B, Ziegler, RG, Perez-Jurado, LA, Caporaso, NE, Rothman, N, Tucker, M, Dean, MC, Yeager, M, and Chanock, SJ

Abstract

To investigate large structural clonal mosaicism of chromosome X, we analysed the SNP microarray intensity data of 38,303 women from cancer genome-wide association studies (20,878 cases and 17,425 controls) and detected 124 mosaic X events >2 Mb in 97 (0.25%) women. Here we show rates for X-chromosome mosaicism are four times higher than mean autosomal rates; X mosaic events more often include the entire chromosome and participants with X events more likely harbour autosomal mosaic events. X mosaicism frequency increases with age (0.11% in 50-year olds; 0.45% in 75-year olds), as reported for Y and autosomes. Methylation array analyses of 33 women with X mosaicism indicate events preferentially involve the inactive X chromosome. Our results provide further evidence that the sex chromosomes undergo mosaic events more frequently than autosomes, which could have implications for understanding the underlying mechanisms of mosaic events and their possible contribution to risk for chronic diseases.

Published
2016

113. 1074 - FGFR3 mutations and their relation to FGFR3 expression and clinical outcome in a large radical cystectomy cohort: Implications for anti-FGFR3 bladder cancer treatment?

Author

Mertens, L.S., Van Rhijn, B.W.G., Mayr, R., Bostrom, P.J., Marquez, M., Zwarthoff, E.C., Boormans, J.L., Abas, C., Van Leenders, G., Neuzillet, Y., Van Der Heijden, M.S., Real, F.X., Stohr, R., Zlotta, A.R., Eckstein, M., Soorojebally, Y., Burger, M., Radvanyi, F., Sirab, N., Pouessel, D., Van Der Kwast, T.H., Malats, N., Hartmann, A., Allory, Y., and Zuiverloon, T.

Published
2019
Full Text
View/download PDF

114. A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46,450 cases and 42,461 controls from the breast cancer association consortium

Author

Rl, Milne, Herranz J, Michailidou K, Joe Dennis, Jp, Tyrer, Mp, Zamora, Ji, Arias-Perez, González-Neira A, Pita G, Alonso MR, Wang Q, Mk, Bolla, Czene K, Eriksson M, Humphreys K, Darabi H, Li J, Anton-Culver H, Sl, Neuhausen, Ziogas A, Ca, Clarke, Jl, Hopper, Gs, Dite, Apicella C, Mc, Southey, Chenevix-Trench G, kConFab Investigators, Australian Ovarian Cancer Study Group, Swerdlow A, Ashworth A, Orr N, Schoemaker M, Jakubowska A, Lubinski J, Jaworska-Bieniek K, Durda K, Il, Andrulis, Ja, Knight, Glendon G, Am, Mulligan, Se, Bojesen, Bg, Nordestgaard, Flyger H, Nevanlinna H, Ta, Muranen, Aittomäki K, Blomqvist C, Chang-Claude J, Rudolph A, Seibold P, Flesch-Janys D, Wang X, Je, Olson, Vachon C, Purrington K, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Grip M, Am, Dunning, Shah M, Guénel P, Truong T, Sanchez M, Mulot C, Brenner H, Ak, Dieffenbach, Arndt V, Stegmaier C, Lindblom A, Margolin S, Hooning M, Hollestelle A, Collée M, Jager A, Cox A, Iw, Brock, Mw, Reed, Devilee P, Ra, Tollenaar, Seynaeve C, Ca, Haiman, Be, Henderson, Schumacher F, Le Marchand L, Simard J, Dumont M, Soucy P, Dörk T, Nv, Bogdanova, Hamann U, Försti A, Rüdiger T, Hu, Ulmer, Pa, Fasching, Häberle L, Ab, Ekici, Mw, Beckmann, Fletcher O, Johnson N, Id, Silva, Peto J, Radice P, Peterlongo P, Peissel B, Mariani P, Gg, Giles, Severi G, Baglietto L, Sawyer E, Tomlinson I, Kerin M, Miller N, Marme F, Burwinkel B, Mannermaa A, Kataja V, Vm, Kosma, Hartikainen J, Lambrechts D, Bt, Yesilyurt, Floris G, Leunen K, Gg, Alnæs, Kristensen V, Al, Børresen-Dale, García-Closas M, Sj, Chanock, Lissowska J, Jd, Figueroa, Mk, Schmidt, Broeks A, Verhoef S, Ej, Rutgers, Brauch H, Brüning T, Yd, Ko, Genica, The Network, Fj, Couch, Ae, Toland, Tnbcc, The, Yannoukakos D, Pd, Pharoah, Hall P, Benítez J, Malats N, and Df, Easton

Subjects
Australian Ovarian Cancer Study Group, Genetics & Heredity, Breast Neoplasms, Epistasis, Genetic, Biological Sciences, TNBCC, Polymorphism, Single Nucleotide, Medical and Health Sciences, Logistic Models, Case-Control Studies, kConFab Investigators, Humans, Genetic Predisposition to Disease, Female, GENICA Network, Genome-Wide Association Study
Abstract

Part of the substantial unexplained familial aggregation of breast cancer may be due to interactions between common variants, but few studies have had adequate statistical power to detect interactions of realistic magnitude. We aimed to assess all two-way interactions in breast cancer susceptibility between 70,917 single nucleotide polymorphisms (SNPs) selected primarily based on prior evidence of a marginal effect. Thirty-eight international studies contributed data for 46,450 breast cancer cases and 42,461 controls of European origin as part of a multi-consortium project (COGS). First, SNPs were preselected based on evidence (P < 0.01) of a per-allele main effect, and all two-way combinations of those were evaluated by a per-allele (1 d.f.) test for interaction using logistic regression. Second, all 2.5 billion possible two-SNP combinations were evaluated using Boolean operation-based screening and testing, and SNP pairs with the strongest evidence of interaction (P < 10(-4)) were selected for more careful assessment by logistic regression. Under the first approach, 3277 SNPs were preselected, but an evaluation of all possible two-SNP combinations (1 d.f.) identified no interactions at P < 10(-8). Results from the second analytic approach were consistent with those from the first (P > 10(-10)). In summary, we observed little evidence of two-way SNP interactions in breast cancer susceptibility, despite the large number of SNPs with potential marginal effects considered and the very large sample size. This finding may have important implications for risk prediction, simplifying the modelling required. Further comprehensive, large-scale genome-wide interaction studies may identify novel interacting loci if the inherent logistic and computational challenges can be overcome.

Published
2014

115. Genome-wide association study identifies multiple loci associated with bladder cancer risk

Author

Figueroa, JD, Ye, Y, Siddiq, A, Garcia-Closas, M, Chatterjee, N, Prokunina-Olsson, L, Cortessis, VK, Kooperberg, C, Cussenot, O, Benhamou, S, Prescott, J, Porru, S, Dinney, CP, Malats, N, Baris, D, Purdue, M, Jacobs, EJ, Albanes, D, Wang, Z, Deng, X, Chung, CC, Tang, W, Bueno-De-Mesquita, HB, Trichopoulos, D, Ljungberg, B, Clavel-Chapelon, F, Weiderpass, E, Krogh, V, Dorronsoro, M, Travis, R, Tjonneland, A, Brenan, P, Chang-Claude, J, Riboli, E, Conti, D, Gago Dominguez, Manuela, Stern, MC, Pike, MC, Van den Berg, D, Yuan, JM, Hohensee, C, Rodabough, R, Cancel-Tassin, G, Roupret, M, Comperat, E, Chen, C, De Vivo, I, Giovannucci, E, Hunter, DJ, Kraft, P, Lindstrom, S, Carta, A, Pavanello, S, Arici, C, Mastrangelo, G, Kamat, AM, Lerner, SP, Grossman, HB, Lin, J, Gu, J, Pu, X, Hutchinson, A, Burdette, L, Wheeler, W, Kogevinas, M, Tardon, A, Serra, C, Carrato, A, Garcia-Closas, R, Lloreta, J, Schwenn, M, Karagas, MR, Johnson, A, Schned, A, Armenti, KR, Hosain, GM, Andriole, G, Grubb, R, Black, A, Diver, WR, Gapstur, SM, Weinstein, SJ, Virtamo, J, Haiman, CA, Landi, MT, Caporaso, N, Fraumeni, JF, Vineis, P, Wu, X, Silverman, DT, Chanock, S, and Rothman, N

Subjects
Risk, Genotype, Meta-Analysis as Topic, Urinary Bladder Neoplasms, Genetic Loci, Case-Control Studies, Humans, Genetic Predisposition to Disease, Polymorphism, Single Nucleotide, Linkage Disequilibrium, Genome-Wide Association Study
Abstract

Candidate gene and genome-wide association studies (GWAS) have identified 11 independent susceptibility loci associated with bladder cancer risk. To discover additional risk variants, we conducted a new GWAS of 2422 bladder cancer cases and 5751 controls, followed by a meta-analysis with two independently published bladder cancer GWAS, resulting in a combined analysis of 6911 cases and 11 814 controls of European descent. TaqMan genotyping of 13 promising single nucleotide polymorphisms with P < 1 x 10(-5) was pursued in a follow-up set of 801 cases and 1307 controls. Two new loci achieved genome-wide statistical significance: rs10936599 on 3q26.2 (P = 4.53 x 10(-9)) and rs907611 on 11p15.5 (P = 4.11 x 10(-8)). Two notable loci were also identified that approached genome-wide statistical significance: rs6104690 on 20p12.2 (P = 7.13 x 10(-7)) and rs4510656 on 6p22.3 (P = 6.98 x 10(-7)); these require further studies for confirmation. In conclusion, our study has identified new susceptibility alleles for bladder cancer risk that require fine-mapping and laboratory investigation, which could further understanding into the biological underpinnings of bladder carcinogenesis.

Published
2014

116. 288 Is two protein immunohistochemistry assay able to identify the basal subtype of bladder cancer?

Author

Masson-Lecomte, A., primary, Sirab, N., additional, De Reyniès, A., additional, Maillé, P., additional, Soyeux-Porte, P., additional, Vordos, D., additional, Lebret, T., additional, Benhamou, S., additional, Carrato, A., additional, Malats, N., additional, Real, F., additional, De La Taille, A., additional, Radvanyi, F., additional, and Allory, Y., additional

Published
2016
Full Text
View/download PDF

117. 747 Bladder cancer and seroreactivity to BK, JC and Merkel cell polyomaviruses: The Spanish bladder cancer study

Author

Garcia-Rojo, D., primary, Robles, C., additional, Viscidi, R., additional, Malats, N., additional, Silverman, D., additional, Gelabert-Mas, A., additional, Ibarz, L., additional, Cecchini, L., additional, Kogevinas, M., additional, Garcia-Closas, R., additional, Prera, A., additional, Lloreta, J., additional, Consol, S., additional, Carrato, A., additional, Abascal, R., additional, Fernandez, J.M., additional, Rodriguez De Vera, J.M., additional, Rivas, M., additional, Guate, J.L., additional, Malet, J.M., additional, Muntañola, P., additional, Gonzalez-Huergo, J., additional, Mosquera, J., additional, Cespedes, M., additional, Prats, J., additional, and Real, F.X., additional

Published
2016
Full Text
View/download PDF

119. Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guerin: results of a retrospective multicenter study of 2451 patients

Author

Gontero, P., Sylvester, R., Pisano, F., Joniau, S., Eeckt, K. Vander, Serretta, V., Larre, S., Stasi, S. Di, Rhijn, B. Van, Witjes, J.A., Grotenhuis, A.J., Kiemeney, L.A.L.M., Colombo, R., Briganti, A., Babjuk, M., Malmstrom, P.U., Oderda, M., Irani, J., Malats, N., Baniel, J., Mano, R., Cai, T., Cha, E.K., Ardelt, P., Varkarakis, J., Bartoletti, R., Spahn, M., Johansson, R., Frea, B., Soukup, V., Xylinas, E., Dalbagni, G., Karnes, R.J., Shariat, S.F., Palou, J., Gontero, P., Sylvester, R., Pisano, F., Joniau, S., Eeckt, K. Vander, Serretta, V., Larre, S., Stasi, S. Di, Rhijn, B. Van, Witjes, J.A., Grotenhuis, A.J., Kiemeney, L.A.L.M., Colombo, R., Briganti, A., Babjuk, M., Malmstrom, P.U., Oderda, M., Irani, J., Malats, N., Baniel, J., Mano, R., Cai, T., Cha, E.K., Ardelt, P., Varkarakis, J., Bartoletti, R., Spahn, M., Johansson, R., Frea, B., Soukup, V., Xylinas, E., Dalbagni, G., Karnes, R.J., Shariat, S.F., and Palou, J.

Abstract

Contains fulltext : 153742.pdf (Publisher’s version ) (Closed access), BACKGROUND: The impact of prognostic factors in T1G3 non-muscle-invasive bladder cancer (BCa) patients is critical for proper treatment decision making. OBJECTIVE: To assess prognostic factors in patients who received bacillus Calmette-Guerin (BCG) as initial intravesical treatment of T1G3 tumors and to identify a subgroup of high-risk patients who should be considered for more aggressive treatment. DESIGN, SETTING, AND PARTICIPANTS: Individual patient data were collected for 2451 T1G3 patients from 23 centers who received BCG between 1990 and 2011. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Using Cox multivariable regression, the prognostic importance of several clinical variables was assessed for time to recurrence, progression, BCa-specific survival, and overall survival (OS). RESULTS AND LIMITATIONS: With a median follow-up of 5.2 yr, 465 patients (19%) progressed, 509 (21%) underwent cystectomy, and 221 (9%) died because of BCa. In multivariable analyses, the most important prognostic factors for progression were age, tumor size, and concomitant carcinoma in situ (CIS); the most important prognostic factors for BCa-specific survival and OS were age and tumor size. Patients were divided into four risk groups for progression according to the number of adverse factors among age >/= 70 yr, size >/= 3 cm, and presence of CIS. Progression rates at 10 yr ranged from 17% to 52%. BCa-specific death rates at 10 yr were 32% in patients >/= 70 yr with tumor size >/= 3 cm and 13% otherwise. CONCLUSIONS: T1G3 patients >/= 70 yr with tumors >/= 3 cm and concomitant CIS should be treated more aggressively because of the high risk of progression. PATIENT SUMMARY: Although the majority of T1G3 patients can be safely treated with intravesical bacillus Calmette-Guerin, there is a subgroup of T1G3 patients with age >/= 70 yr, tumor size >/= 3 cm, and concomitant CIS who have a high risk of progression and thus require aggressive treatment.

Published
2015

120. Vitamin D Metabolic Pathway Genes and Pancreatic Cancer Risk

Author

Chang, JS, Arem, H, Yu, K, Xiong, X, Moy, K, Freedman, ND, Mayne, ST, Albanes, D, Arslan, AA, Austin, M, Bamlet, WR, Beane-Freeman, L, Bracci, P, Canzian, F, Cotterchio, M, Duell, EJ, Gallinger, S, Giles, GG, Goggins, M, Goodman, PJ, Hartge, P, Hassan, M, Helzlsouer, K, Henderson, B, Holly, EA, Hoover, R, Jacobs, EJ, Kamineni, A, Klein, A, Klein, E, Kolonel, LN, Li, D, Malats, N, Mannisto, S, McCullough, ML, Olson, SH, Orlow, I, Peters, U, Petersen, GM, Porta, M, Severi, G, Shu, X-O, Visvanathan, K, White, E, Yu, H, Zeleniuch-Jacquotte, A, Zheng, W, Tobias, GS, Maeder, D, Brotzman, M, Risch, H, Sampson, JN, Stolzenberg-Solomon, RZ, Chang, JS, Arem, H, Yu, K, Xiong, X, Moy, K, Freedman, ND, Mayne, ST, Albanes, D, Arslan, AA, Austin, M, Bamlet, WR, Beane-Freeman, L, Bracci, P, Canzian, F, Cotterchio, M, Duell, EJ, Gallinger, S, Giles, GG, Goggins, M, Goodman, PJ, Hartge, P, Hassan, M, Helzlsouer, K, Henderson, B, Holly, EA, Hoover, R, Jacobs, EJ, Kamineni, A, Klein, A, Klein, E, Kolonel, LN, Li, D, Malats, N, Mannisto, S, McCullough, ML, Olson, SH, Orlow, I, Peters, U, Petersen, GM, Porta, M, Severi, G, Shu, X-O, Visvanathan, K, White, E, Yu, H, Zeleniuch-Jacquotte, A, Zheng, W, Tobias, GS, Maeder, D, Brotzman, M, Risch, H, Sampson, JN, and Stolzenberg-Solomon, RZ

Abstract

Evidence on the association between vitamin D status and pancreatic cancer risk is inconsistent. This inconsistency may be partially attributable to variation in vitamin D regulating genes. We selected 11 vitamin D-related genes (GC, DHCR7, CYP2R1, VDR, CYP27B1, CYP24A1, CYP27A1, RXRA, CRP2, CASR and CUBN) totaling 213 single nucleotide polymorphisms (SNPs), and examined associations with pancreatic adenocarcinoma. Our study included 3,583 pancreatic cancer cases and 7,053 controls from the genome-wide association studies of pancreatic cancer PanScans-I-III. We used the Adaptive Joint Test and the Adaptive Rank Truncated Product statistic for pathway and gene analyses, and unconditional logistic regression for SNP analyses, adjusting for age, sex, study and population stratification. We examined effect modification by circulating vitamin D concentration (≤50, >50 nmol/L) for the most significant SNPs using a subset of cohort cases (n = 713) and controls (n = 878). The vitamin D metabolic pathway was not associated with pancreatic cancer risk (p = 0.830). Of the individual genes, none were associated with pancreatic cancer risk at a significance level of p<0.05. SNPs near the VDR (rs2239186), LRP2 (rs4668123), CYP24A1 (rs2762932), GC (rs2282679), and CUBN (rs1810205) genes were the top SNPs associated with pancreatic cancer (p-values 0.008-0.037), but none were statistically significant after adjusting for multiple comparisons. Associations between these SNPs and pancreatic cancer were not modified by circulating concentrations of vitamin D. These findings do not support an association between vitamin D-related genes and pancreatic cancer risk. Future research should explore other pathways through which vitamin D status might be associated with pancreatic cancer risk.

Published
2015

121. Vitamin D Metabolic Pathway Genes and Pancreatic Cancer Risk (vol 10, e0117574, 2015)

Author

Arem, H, Yu, K, Xiong, X, Moy, K, Freedman, ND, Mayne, ST, Albanes, D, Amundadottir, LT, Arslan, AA, Austin, M, Bamlet, WR, Beane-Freeman, L, Bracci, P, Canzian, F, Chanock, SJ, Cotterchio, M, Duell, EJ, Gallinger, S, Giles, GG, Goggins, M, Goodman, PJ, Hartge, P, Hassan, M, Helzlsouer, K, Henderson, B, Holly, EA, Hoover, R, Jacobs, EJ, Kamineni, A, Klein, A, Klein, E, Kolonel, LN, Li, D, Malats, N, Maennistoe, S, McCullough, ML, Olson, SH, Orlow, I, Peters, U, Petersen, GM, Porta, M, Severi, G, Shu, X-O, Van den Eeden, S, Visvanathan, K, White, E, Yu, H, Zeleniuch-Jacquotte, A, Zheng, W, Tobias, GS, Maeder, D, Brotzman, M, Risch, H, Sampson, JN, Stolzenberg-Solomon, RZ, Arem, H, Yu, K, Xiong, X, Moy, K, Freedman, ND, Mayne, ST, Albanes, D, Amundadottir, LT, Arslan, AA, Austin, M, Bamlet, WR, Beane-Freeman, L, Bracci, P, Canzian, F, Chanock, SJ, Cotterchio, M, Duell, EJ, Gallinger, S, Giles, GG, Goggins, M, Goodman, PJ, Hartge, P, Hassan, M, Helzlsouer, K, Henderson, B, Holly, EA, Hoover, R, Jacobs, EJ, Kamineni, A, Klein, A, Klein, E, Kolonel, LN, Li, D, Malats, N, Maennistoe, S, McCullough, ML, Olson, SH, Orlow, I, Peters, U, Petersen, GM, Porta, M, Severi, G, Shu, X-O, Van den Eeden, S, Visvanathan, K, White, E, Yu, H, Zeleniuch-Jacquotte, A, Zheng, W, Tobias, GS, Maeder, D, Brotzman, M, Risch, H, Sampson, JN, and Stolzenberg-Solomon, RZ

Published
2015

125. Searching for urine biomarkers of bladder cancer recurrence using a liquid chromatography-mass spectrometry and capillary electrophoresis-mass spectrometry metabolomics approach

Author

Alberice, JV, Amaral, AFS, Armitage, EG, Lorente, JA, Algaba, F, Carrilho, E, Marquez, M, Garcia, A, Malats, N, and Barbas, C

Subjects
Progression, Bladder cancer, Metabolomics, Urine, Biomarkers
Abstract

The incidence and rate of recurrence of bladder cancer is high, particularly in developed countries, however current methods for diagnosis are limited to detecting high-grade tumours using often invasive methods. A panel of biomarkers to characterise tumours of different grades that could also distinguish between patients exhibiting the disease with first incidence or recurrence could be useful for bladder cancer diagnostics. In this study, potential metabolic biomarkers have been discovered through mass spectrometry based metabolomics of urine. Pre-treatment urine samples were collected from 48 patients diagnosed of urothelial bladder cancer. Patients were followed-up through the hospital pathological charts to identify whether and when the disease recurred or progressed. Subsequently, they were classified according to whether or not they suffered a tumour recurrence (recurrent or stable) as well as their risk group according to tumour grade and stage. Identified metabolites have been analysed in terms of disease characteristics (tumour stage and recurrence) and have provided an insight into bladder cancer progression. Using both liquid chromatography and capillary electrophoresis-mass spectrometry, a total of 27 metabolite features were highlighted as significantly different between patient groups. Some, for example histidine, phenylalanine, tyrosine and tryptophan have been previously linked with bladder cancer, however until now their connection with bladder cancer progression has not been previously reported. The candidate biomarkers revealed in this study could be useful in the clinic for diagnosis of bladder cancer and, through characterising the stage of the disease, could also be useful in prognostics. (C) 2013 Elsevier B.V. All rights reserved.

Published
2013

126. Assessing interactions between the associations\ud of common genetic susceptibility variants,\ud reproductive history and body mass index with\ud breast cancer risk in the breast cancer association\ud consortium: a combined case-control study

Author

Milne, R.L., Gaudet, M.M., Spurdle, A.B., Fasching, P.A., Couch, F.J., Benitez, J., Perez, J.I.A., Zamora, M.P., Malats, N., Silva, I.D., Gibson, L.J., Fletcher, O., Johnson, N., Anton-Culver, H., Ziogas, A., Figueroa, J., Brinton, L., Sherman, M.E., Lissowska, J., Hopper, J.L., Dite, G.S., Apicella, C., Southey, M.C., Sigurdson, A.J., Linet, M.S., Schonfeld, S.J., Freedman, D.M., Mannermaa, A., Kosma, V.M., Kataja, V., Auvinen, P., Andrulis, I.L., Glendon, G., Knight, J.A., Weerasooriya, N., Cox, A., Reed, M.W.R., Cross, S.S., Dunning, A.M., Ahmed, S., Shah, M., Brauch, H., Ko, Y.D., Bruning, T., Lambrechts, D., Reumers, J., Smeets, A., Wang-Gohrke, S., Hall, P., Czene, K., Liu, J.J., Irwanto, A.K., Chenevix-Trench, G., Holland, H., Giles, G.G., Baglietto, L., Severi, G., Bojensen, S.E., Nordestgaard, B.G., Flyger, H., John, E.M., West, D.W., Whittemore, A.S., Vachon, C., Olson, J.E., Fredericksen, Z., Kosel, M., Hein, R., Vrieling, A., Flesch-Janys, D., Heinz, J., Beckmann, M.W., Heusinger, K., Ekici, A.B., Haeberle, L., Humphreys, M.K., Morrison, J., Easton, D.F., Pharoah, P.D., Garcia-Closas, M., Goode, E.L., Chang-Claude, J., Network, GENICA, Investigators, KConFab, and Group, AOCS

Abstract

Introduction: Several common breast cancer genetic susceptibility variants have recently been identified. We\ud aimed to determine how these variants combine with a subset of other known risk factors to influence breast\ud cancer risk in white women of European ancestry using case-control studies participating in the Breast Cancer\ud Association Consortium.\ud Methods: We evaluated two-way interactions between each of age at menarche, ever having had a live birth,\ud number of live births, age at first birth and body mass index (BMI) and each of 12 single nucleotide\ud polymorphisms (SNPs) (10q26-rs2981582 (FGFR2), 8q24-rs13281615, 11p15-rs3817198 (LSP1), 5q11-rs889312\ud (MAP3K1), 16q12-rs3803662 (TOX3), 2q35-rs13387042, 5p12-rs10941679 (MRPS30), 17q23-rs6504950 (COX11), 3p24-rs4973768 (SLC4A7), CASP8-rs17468277, TGFB1-rs1982073 and ESR1-rs3020314). Interactions were tested for by\ud fitting logistic regression models including per-allele and linear trend main effects for SNPs and risk factors,\ud respectively, and single-parameter interaction terms for linear departure from independent multiplicative effects.\ud Results: These analyses were applied to data for up to 26,349 invasive breast cancer cases and up to 32,208\ud controls from 21 case-control studies. No statistical evidence of interaction was observed beyond that expected by\ud chance. Analyses were repeated using data from 11 population-based studies, and results were very similar.\ud Conclusions: The relative risks for breast cancer associated with the common susceptibility variants identified to\ud date do not appear to vary across women with different reproductive histories or body mass index (BMI). The\ud assumption of multiplicative combined effects for these established genetic and other risk factors in risk prediction\ud models appears justified.

Published
2010

127. PanGen-Fam: Spanish registry of hereditary pancreatic cancer

Author

Mocci, E., primary, Guillen-Ponce, C., additional, Earl, J., additional, Marquez, M., additional, Solera, J., additional, Salazar-López, M.-T., additional, Calcedo-Arnáiz, C., additional, Vázquez-Sequeiros, E., additional, Montans, J., additional, Muñoz-Beltrán, M., additional, Vicente-Bártulos, A., additional, González-Gordaliza, C., additional, Sanjuanbenito, A., additional, Guerrero, C., additional, Mendía, E., additional, Lisa, E., additional, Lobo, E., additional, Martínez, J.C., additional, Real, F.X., additional, Malats, N., additional, and Carrato, A., additional

Published
2015
Full Text
View/download PDF

128. 428 KRAS mutant circulating free DNA (cfDNA) and circulating tumor cell (CTC) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer

Author

Earl, J., primary, Garcia-Nieto, S., additional, Martinez-Avila, J.C., additional, Montans, J., additional, Sanjuanbenito, A., additional, Rodríguez-Garrote, M., additional, Lisa, E., additional, Mendia, E., additional, Lobo, E., additional, Malats, N., additional, Carrato, A., additional, and Guillen, C., additional

Published
2015
Full Text
View/download PDF

130. 948 The impact of different BCG strains on outcome in a large cohort of T1G3 patients treated with BCG

Author

Pisano, F., primary, Witjes, J.A., additional, Dalbagni, G., additional, Shariat, S., additional, Joniau, S., additional, Serretta, V., additional, Palou, J., additional, Di Stasi, S., additional, Larré, S., additional, Colombo, R., additional, Babjuk, M., additional, Malmstrom, P.U., additional, Irani, J., additional, Malats, N., additional, Baniel, J., additional, Cai, T., additional, Cha, E., additional, Ardelt, P., additional, Varkarakis, J., additional, Bartoletti, R., additional, Spahn, M., additional, Pisano, F., additional, Gontero, P., additional, and Sylvester, R., additional

Published
2015
Full Text
View/download PDF

131. Identification of new genetic susceptibility loci for breast cancer through consideration of gene-environment interactions

Author

Schoeps, A., Rudolph, A., Seibold, P., Dunning, A.M., Milne, R.L., Bojesen, S.E., Swerdlow, A., Andrulis, I., Brenner, H., Behrens, S., Orr, N., Jones, M., Ashworth, A., Li, J., Cramp, H., Connley, D., Czene, K., Darabi, H., Chanock, S.J., Lissowska, J., Figueroa, J.D., Knight, J., Glendon, G., Mulligan, A.M., Dumont, M., Severi, G., Baglietto, L., Olson, J., Vachon, C., Purrington, K., Moisse, M., Neven, P., Wildiers, H., Spurdle, A., Kosma, V.M., Kataja, V., Hartikainen, J.M., Hamann, U., Ko, Y.D., Dieffenbach, A.K., Arndt, V., Stegmaier, C., Malats, N., Perez, J.I., Benitez, J., Flyger, H., Nordestgaard, B.G., Truong, T., Cordina-Duverger, E., Menegaux, F., dos Santos Silva, I., Fletcher, O., Johnson, N., Haberle, L., Beckmann, M.W., Ekici, A.B., Braaf, L., Atsma, F., Broek, A.J. van den, Makalic, E., Schmidt, D.F., Southey, M.C., Cox, A, Simard, J., Giles, G.G., Lambrechts, D., Mannermaa, A., Brauch, H., Guenel, P., Peto, J., Fasching, P.A., Hopper, J., Flesch-Janys, D., Couch, F., Chenevix-Trench, G., Pharoah, P.D., Garcia-Closas, M., Schmidt, M.K., Hall, P., Easton, D.F., Chang-Claude, J., Schoeps, A., Rudolph, A., Seibold, P., Dunning, A.M., Milne, R.L., Bojesen, S.E., Swerdlow, A., Andrulis, I., Brenner, H., Behrens, S., Orr, N., Jones, M., Ashworth, A., Li, J., Cramp, H., Connley, D., Czene, K., Darabi, H., Chanock, S.J., Lissowska, J., Figueroa, J.D., Knight, J., Glendon, G., Mulligan, A.M., Dumont, M., Severi, G., Baglietto, L., Olson, J., Vachon, C., Purrington, K., Moisse, M., Neven, P., Wildiers, H., Spurdle, A., Kosma, V.M., Kataja, V., Hartikainen, J.M., Hamann, U., Ko, Y.D., Dieffenbach, A.K., Arndt, V., Stegmaier, C., Malats, N., Perez, J.I., Benitez, J., Flyger, H., Nordestgaard, B.G., Truong, T., Cordina-Duverger, E., Menegaux, F., dos Santos Silva, I., Fletcher, O., Johnson, N., Haberle, L., Beckmann, M.W., Ekici, A.B., Braaf, L., Atsma, F., Broek, A.J. van den, Makalic, E., Schmidt, D.F., Southey, M.C., Cox, A, Simard, J., Giles, G.G., Lambrechts, D., Mannermaa, A., Brauch, H., Guenel, P., Peto, J., Fasching, P.A., Hopper, J., Flesch-Janys, D., Couch, F., Chenevix-Trench, G., Pharoah, P.D., Garcia-Closas, M., Schmidt, M.K., Hall, P., Easton, D.F., and Chang-Claude, J.

Abstract

Item does not contain fulltext, Genes that alter disease risk only in combination with certain environmental exposures may not be detected in genetic association analysis. By using methods accounting for gene-environment (G x E) interaction, we aimed to identify novel genetic loci associated with breast cancer risk. Up to 34,475 cases and 34,786 controls of European ancestry from up to 23 studies in the Breast Cancer Association Consortium were included. Overall, 71,527 single nucleotide polymorphisms (SNPs), enriched for association with breast cancer, were tested for interaction with 10 environmental risk factors using three recently proposed hybrid methods and a joint test of association and interaction. Analyses were adjusted for age, study, population stratification, and confounding factors as applicable. Three SNPs in two independent loci showed statistically significant association: SNPs rs10483028 and rs2242714 in perfect linkage disequilibrium on chromosome 21 and rs12197388 in ARID1B on chromosome 6. While rs12197388 was identified using the joint test with parity and with age at menarche (P-values = 3 x 10(-07)), the variants on chromosome 21 q22.12, which showed interaction with adult body mass index (BMI) in 8,891 postmenopausal women, were identified by all methods applied. SNP rs10483028 was associated with breast cancer in women with a BMI below 25 kg/m(2) (OR = 1.26, 95% CI 1.15-1.38) but not in women with a BMI of 30 kg/m(2) or higher (OR = 0.89, 95% CI 0.72-1.11, P for interaction = 3.2 x 10(-05)). Our findings confirm comparable power of the recent methods for detecting G x E interaction and the utility of using G x E interaction analyses to identify new susceptibility loci.

Published
2014

132. Telomerase reverse transcriptase promoter mutations in bladder cancer: High frequency across stages, detection in urine, and lack of association with outcome

Author

Allory, Y. (Yves), Beukers, W. (Willemien), Sagrera, A. (Ana), Flández, M. (Marta), Marqués, M. (Miriam), Márquez, M. (Mirari), Keur, K.A. (Kirstin) van der, Dyrskjot, L. (Lars), Lurkin, I. (Irene), Vermeij, M. (Marcel), Carrato, A. (Alfredo), Lloreta, J. (Josep), Lorente, J.A. (José), Carrillo-de Santa Pau, E. (Enrique), Masius, R.G. (Roy), Kogevinas, M. (Manolis), Steyerberg, E.W. (Ewout), Tilborg, A.A.G. (Angela) van, Abas, C.S. (Cheno), Orntoft, T.F. (Torben), Zuiverloon, T.C.M. (Tahlita), Malats, N. (Núria), Zwarthoff, E.C. (Ellen), Real, F.X. (Francisco), Allory, Y. (Yves), Beukers, W. (Willemien), Sagrera, A. (Ana), Flández, M. (Marta), Marqués, M. (Miriam), Márquez, M. (Mirari), Keur, K.A. (Kirstin) van der, Dyrskjot, L. (Lars), Lurkin, I. (Irene), Vermeij, M. (Marcel), Carrato, A. (Alfredo), Lloreta, J. (Josep), Lorente, J.A. (José), Carrillo-de Santa Pau, E. (Enrique), Masius, R.G. (Roy), Kogevinas, M. (Manolis), Steyerberg, E.W. (Ewout), Tilborg, A.A.G. (Angela) van, Abas, C.S. (Cheno), Orntoft, T.F. (Torben), Zuiverloon, T.C.M. (Tahlita), Malats, N. (Núria), Zwarthoff, E.C. (Ellen), and Real, F.X. (Francisco)

Abstract

Background Hotspot mutations in the promoter of the gene coding for telomerase reverse transcriptase (TERT) have been described and proposed to activate gene expression. Objectives To investigate TERT mutation frequency, spectrum, association with expression and clinical outcome, and potential for detection of recurrences in urine in patients with urothelial bladder cancer (UBC). De

Published
2014
Full Text
View/download PDF

133. Risk prediction scores for recurrence and progression of non-muscle invasive bladder cancer

Author

Vedder, M.M. (Moniek), Márquez, M. (Mirari), Bekker-Grob, E.W. (Esther) de, Calle, M.L. (Malu), Dyrskjot, L. (Lars), Kogevinas, M. (Manolis), Segersten, U. (Ulrika), Malmström, P.-U. (Per-Uno), Algaba, F. (Ferran), Beukers, W. (Willemien), Orntoft, T.F. (Torben), Zwarthoff, E.C. (Ellen), Real, F.X. (Francisco), Malats, N. (Núria), Steyerberg, E.W. (Ewout), Vedder, M.M. (Moniek), Márquez, M. (Mirari), Bekker-Grob, E.W. (Esther) de, Calle, M.L. (Malu), Dyrskjot, L. (Lars), Kogevinas, M. (Manolis), Segersten, U. (Ulrika), Malmström, P.-U. (Per-Uno), Algaba, F. (Ferran), Beukers, W. (Willemien), Orntoft, T.F. (Torben), Zwarthoff, E.C. (Ellen), Real, F.X. (Francisco), Malats, N. (Núria), and Steyerberg, E.W. (Ewout)

Abstract

Objective: We aimed to determine the validity of two risk scores for patients with non-muscle invasive bladder cancer in different European settings, in patients with primary tumours. Methods: We included 1,892 patients with primary stage Ta or T1 non-muscle invasive bladder cancer who underwent a transurethral resection in Spain (n = 973), the Netherlands (n = 639), or Denmark (n = 280). We evaluated recurrence-free survival and progression-free survival according to the European Organisation for Research a

Published
2014
Full Text
View/download PDF

134. Improving the Transparency of Prognosis Research: The Role of Reporting, Data Sharing, Registration, and Protocols

Author

Peat, G., Riley, R.D. (Richard), Morley, K.I. (Katherine), Kyzas, P.A. (Panayiotis), Moons, K.G.M. (Karel), Perel, P. (Pablo), Schroter, S. (Sara), Altman, D.G. (Douglas), Abrams, D., Briggs, A. (Andrew), Brünner, N. (Nils Age), Croft, P. (Peter), Hayden, J. (Jill), Hingorani, A. (Aroon), Hemingway, H., Kyzas, P. (Panayiotis), Malats, N. (Núria), Roberts, I. (Ian), Sauerbrei, W. (Willi), Steyerberg, E.W. (Ewout), Timmis, A. (Adam), Windt, D.A.W.M. (Daniëlle) van der, Peat, G., Riley, R.D. (Richard), Morley, K.I. (Katherine), Kyzas, P.A. (Panayiotis), Moons, K.G.M. (Karel), Perel, P. (Pablo), Schroter, S. (Sara), Altman, D.G. (Douglas), Abrams, D., Briggs, A. (Andrew), Brünner, N. (Nils Age), Croft, P. (Peter), Hayden, J. (Jill), Hingorani, A. (Aroon), Hemingway, H., Kyzas, P. (Panayiotis), Malats, N. (Núria), Roberts, I. (Ian), Sauerbrei, W. (Willi), Steyerberg, E.W. (Ewout), Timmis, A. (Adam), and Windt, D.A.W.M. (Daniëlle) van der

Published
2014
Full Text
View/download PDF

135. Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer

Author

Wolpin, BM, Rizzato, C, Kraft, P, Kooperberg, C, Petersen, GM, Wang, Z, Arslan, AA, Beane-Freeman, L, Bracci, PM, Buring, J, Canzian, F, Duell, EJ, Gallinger, S, Giles, GG, Goodman, GE, Goodman, PJ, Jacobs, EJ, Kamineni, A, Klein, AP, Kolonel, LN, Kulke, MH, Li, D, Malats, N, Olson, SH, Risch, HA, Sesso, HD, Visvanathan, K, White, E, Zheng, W, Abnet, CC, Albanes, D, Andreotti, G, Austin, MA, Barfield, R, Basso, D, Berndt, SI, Boutron-Ruault, M-C, Brotzman, M, Buechler, MW, Bueno-de-Mesquita, HB, Bugert, P, Burdette, L, Campa, D, Caporaso, NE, Capurso, G, Chung, C, Cotterchio, M, Costello, E, Elena, J, Funel, N, Gaziano, JM, Giese, NA, Goggins, M, Gorman, MJ, Gross, M, Haiman, CA, Hassan, M, Helzlsouer, KJ, Henderson, BE, Holly, EA, Hu, N, Hunter, DJ, Innocenti, F, Jenab, M, Kaaks, R, Key, TJ, Khaw, K-T, Klein, EA, Kogevinas, M, Krogh, V, Kupcinskas, J, Kurtz, RC, LaCroix, A, Landi, MT, Landi, S, Le Marchand, L, Mambrini, A, Mannisto, S, Milne, RL, Nakamura, Y, Oberg, AL, Owzar, K, Patel, AV, Peeters, PHM, Peters, U, Pezzilli, R, Piepoli, A, Porta, M, Real, FX, Riboli, E, Rothman, N, Scarpa, A, Shu, X-O, Silverman, DT, Soucek, P, Sund, M, Talar-Wojnarowska, R, Taylor, PR, Theodoropoulos, GE, Thornquist, M, Tjonneland, A, Tobias, GS, Trichopoulos, D, Vodicka, P, Wactawski-Wende, J, Wentzensen, N, Wu, C, Yu, H, Yu, K, Zeleniuch-Jacquotte, A, Hoover, R, Hartge, P, Fuchs, C, Chanock, SJ, Stolzenberg-Solomon, RS, Amundadottir, LT, Wolpin, BM, Rizzato, C, Kraft, P, Kooperberg, C, Petersen, GM, Wang, Z, Arslan, AA, Beane-Freeman, L, Bracci, PM, Buring, J, Canzian, F, Duell, EJ, Gallinger, S, Giles, GG, Goodman, GE, Goodman, PJ, Jacobs, EJ, Kamineni, A, Klein, AP, Kolonel, LN, Kulke, MH, Li, D, Malats, N, Olson, SH, Risch, HA, Sesso, HD, Visvanathan, K, White, E, Zheng, W, Abnet, CC, Albanes, D, Andreotti, G, Austin, MA, Barfield, R, Basso, D, Berndt, SI, Boutron-Ruault, M-C, Brotzman, M, Buechler, MW, Bueno-de-Mesquita, HB, Bugert, P, Burdette, L, Campa, D, Caporaso, NE, Capurso, G, Chung, C, Cotterchio, M, Costello, E, Elena, J, Funel, N, Gaziano, JM, Giese, NA, Goggins, M, Gorman, MJ, Gross, M, Haiman, CA, Hassan, M, Helzlsouer, KJ, Henderson, BE, Holly, EA, Hu, N, Hunter, DJ, Innocenti, F, Jenab, M, Kaaks, R, Key, TJ, Khaw, K-T, Klein, EA, Kogevinas, M, Krogh, V, Kupcinskas, J, Kurtz, RC, LaCroix, A, Landi, MT, Landi, S, Le Marchand, L, Mambrini, A, Mannisto, S, Milne, RL, Nakamura, Y, Oberg, AL, Owzar, K, Patel, AV, Peeters, PHM, Peters, U, Pezzilli, R, Piepoli, A, Porta, M, Real, FX, Riboli, E, Rothman, N, Scarpa, A, Shu, X-O, Silverman, DT, Soucek, P, Sund, M, Talar-Wojnarowska, R, Taylor, PR, Theodoropoulos, GE, Thornquist, M, Tjonneland, A, Tobias, GS, Trichopoulos, D, Vodicka, P, Wactawski-Wende, J, Wentzensen, N, Wu, C, Yu, H, Yu, K, Zeleniuch-Jacquotte, A, Hoover, R, Hartge, P, Fuchs, C, Chanock, SJ, Stolzenberg-Solomon, RS, and Amundadottir, LT

Abstract

We performed a multistage genome-wide association study including 7,683 individuals with pancreatic cancer and 14,397 controls of European descent. Four new loci reached genome-wide significance: rs6971499 at 7q32.3 (LINC-PINT, per-allele odds ratio (OR) = 0.79, 95% confidence interval (CI) 0.74-0.84, P = 3.0 × 10(-12)), rs7190458 at 16q23.1 (BCAR1/CTRB1/CTRB2, OR = 1.46, 95% CI 1.30-1.65, P = 1.1 × 10(-10)), rs9581943 at 13q12.2 (PDX1, OR = 1.15, 95% CI 1.10-1.20, P = 2.4 × 10(-9)) and rs16986825 at 22q12.1 (ZNRF3, OR = 1.18, 95% CI 1.12-1.25, P = 1.2 × 10(-8)). We identified an independent signal in exon 2 of TERT at the established region 5p15.33 (rs2736098, OR = 0.80, 95% CI 0.76-0.85, P = 9.8 × 10(-14)). We also identified a locus at 8q24.21 (rs1561927, P = 1.3 × 10(-7)) that approached genome-wide significance located 455 kb telomeric of PVT1. Our study identified multiple new susceptibility alleles for pancreatic cancer that are worthy of follow-up studies.

Published
2014

136. Genetic Variation in the TP53 Pathway and Bladder Cancer Risk. A Comprehensive Analysis

Author

Katoh, M, Pineda, S, Milne, RL, Luz Calle, M, Rothman, N, Lopez de Maturana, E, Herranz, J, Kogevinas, M, Chanock, SJ, Tardon, A, Marquez, M, Guey, LT, Garcia-Closas, M, Lloreta, J, Baum, E, Gonzalez-Neira, A, Carrato, A, Navarro, A, Silverman, DT, Real, FX, Malats, N, Katoh, M, Pineda, S, Milne, RL, Luz Calle, M, Rothman, N, Lopez de Maturana, E, Herranz, J, Kogevinas, M, Chanock, SJ, Tardon, A, Marquez, M, Guey, LT, Garcia-Closas, M, Lloreta, J, Baum, E, Gonzalez-Neira, A, Carrato, A, Navarro, A, Silverman, DT, Real, FX, and Malats, N

Abstract

INTRODUCTION: Germline variants in TP63 have been consistently associated with several tumors, including bladder cancer, indicating the importance of TP53 pathway in cancer genetic susceptibility. However, variants in other related genes, including TP53 rs1042522 (Arg72Pro), still present controversial results. We carried out an in depth assessment of associations between common germline variants in the TP53 pathway and bladder cancer risk. MATERIAL AND METHODS: We investigated 184 tagSNPs from 18 genes in 1,058 cases and 1,138 controls from the Spanish Bladder Cancer/EPICURO Study. Cases were newly-diagnosed bladder cancer patients during 1998-2001. Hospital controls were age-gender, and area matched to cases. SNPs were genotyped in blood DNA using Illumina Golden Gate and TaqMan assays. Cases were subphenotyped according to stage/grade and tumor p53 expression. We applied classical tests to assess individual SNP associations and the Least Absolute Shrinkage and Selection Operator (LASSO)-penalized logistic regression analysis to assess multiple SNPs simultaneously. RESULTS: Based on classical analyses, SNPs in BAK1 (1), IGF1R (5), P53AIP1 (1), PMAIP1 (2), SERINPB5 (3), TP63 (3), and TP73 (1) showed significant associations at p-value≤0.05. However, no evidence of association, either with overall risk or with specific disease subtypes, was observed after correction for multiple testing (p-value≥0.8). LASSO selected the SNP rs6567355 in SERPINB5 with 83% of reproducibility. This SNP provided an OR = 1.21, 95%CI 1.05-1.38, p-value = 0.006, and a corrected p-value = 0.5 when controlling for over-estimation. DISCUSSION: We found no strong evidence that common variants in the TP53 pathway are associated with bladder cancer susceptibility. Our study suggests that it is unlikely that TP53 Arg72Pro is implicated in the UCB in white Europeans. SERPINB5 and TP63 variation deserve further exploration in extended studies.

Published
2014

137. Telomerase Reverse Transcriptase Promoter Mutations in Bladder Cancer: High Frequency Across Stages, Detection in Urine, and Lack of Association with Outcome

Author

Allory, Y, Beukers, Willemien, Sagrera, A, Flandez, M, Marques, M, Marquez, M, Keur, Kirstin, Dyrskjot, L, Lurkin, Irene, Vermeij, Marcel, Carrato, A, Lloreta, J, Lorente, JA, Pau, ECD, Masius, Roy, Kogevinas, M, Steyerberg, Ewout, van Tilborg, AAG, Abas, C, Orntoft, TF, Zuiverloon, Tahlita, Malats, N, Zwarthoff, Ellen, Real, FX, Allory, Y, Beukers, Willemien, Sagrera, A, Flandez, M, Marques, M, Marquez, M, Keur, Kirstin, Dyrskjot, L, Lurkin, Irene, Vermeij, Marcel, Carrato, A, Lloreta, J, Lorente, JA, Pau, ECD, Masius, Roy, Kogevinas, M, Steyerberg, Ewout, van Tilborg, AAG, Abas, C, Orntoft, TF, Zuiverloon, Tahlita, Malats, N, Zwarthoff, Ellen, and Real, FX

Abstract

Background: Hotspot mutations in the promoter of the gene coding for telomerase reverse transcriptase (TERT) have been described and proposed to activate gene expression. Objectives: To investigate TERT mutation frequency, spectrum, association with expression and clinical outcome, and potential for detection of recurrences in urine in patients with urothelial bladder cancer (UBC). Design, setting, and participants: A set of 111 UBCs of different stages was used to assess TERT promoter mutations by Sanger sequencing and TERT messenger RNA (mRNA) expression by reverse transcription-quantitative polymerase chain reaction. The two most frequent mutations were investigated, using a SNaPshot assay, in an independent set of 184 non-muscle-invasive and 173 muscle-invasive UBC (median follow-up: 53 mo and 21 mo, respectively). Voided urine from patients with suspicion of incident UBC (n = 174), or under surveillance after diagnosis of non-muscle-invasive UBC (n = 194), was tested using a SNaPshot assay. Outcome measurements and statistical analysis: Association of mutation status with age, sex, tobacco, stage, grade, fibroblast growth factor receptor 3 (FGFR3) mutation, progression-free survival, disease-specific survival, and overall survival. Results and limitations: In the two series, 78 of 111 (70%) and 283 of 357 (79%) tumors harbored TERT mutations, C228T being the most frequent substitution (83% for both series). TERT mutations were not associated with clinical or pathologic parameters, but were more frequent among FGFR3 mutant tumors (p = 0.0002). There was no association between TERT mutations and mRNA expression (p = 0.3). Mutations were not associated with clinical outcome. In urine, TERT mutations had 90% specificity in subjects with hematuria but no bladder tumor, and 73% in recurrence-free UBC patients. The sensitivity was 62% in incident and 42% in recurrent UBC. A limitation of the study is its retrospective nature. Conclusions: Somatic TERT promoter mutatio

Published
2014

138. Risk Prediction Scores for Recurrence and Progression of Non-Muscle Invasive Bladder Cancer: An International Validation in Primary Tumours

Author

Vedder, Moniek, Marquez, M, de Bekker - Grob, Esther, Calle, ML, Dyrskjot, L, Kogevinas, M, Segersten, U, Malmstrom, PU, Algaba, F, Beukers, Willemien, Orntoft, TF, Zwarthoff, Ellen, Real, FX, Malats, N, Steyerberg, Ewout, Vedder, Moniek, Marquez, M, de Bekker - Grob, Esther, Calle, ML, Dyrskjot, L, Kogevinas, M, Segersten, U, Malmstrom, PU, Algaba, F, Beukers, Willemien, Orntoft, TF, Zwarthoff, Ellen, Real, FX, Malats, N, and Steyerberg, Ewout

Abstract

Objective: We aimed to determine the validity of two risk scores for patients with non-muscle invasive bladder cancer in different European settings, in patients with primary tumours. Methods: We included 1,892 patients with primary stage Ta or T1 non-muscle invasive bladder cancer who underwent a transurethral resection in Spain (n = 973), the Netherlands (n = 639), or Denmark (n = 280). We evaluated recurrence-free survival and progression-free survival according to the European Organisation for Research and Treatment of Cancer (EORTC) and the Spanish Urological Club for Oncological Treatment (CUETO) risk scores for each patient and used the concordance index (c-index) to indicate discriminative ability. Results: The 3 cohorts were comparable according to age and sex, but patients from Denmark had a larger proportion of patients with the high stage and grade at diagnosis (p < 0.01). At least one recurrence occurred in 839 (44%) patients and 258 (14%) patients had a progression during a median follow-up of 74 months. Patients from Denmark had the highest 10-year recurrence and progression rates (75% and 24%, respectively), whereas patients from Spain had the lowest rates (34% and 10%, respectively). The EORTC and CUETO risk scores both predicted progression better than recurrence with c-indices ranging from 0.72 to 0.82 while for recurrence, those ranged from 0.55 to 0.61. Conclusion: The EORTC and CUETO risk scores can reasonably predict progression, while prediction of recurrence is more difficult. New prognostic markers are needed to better predict recurrence of tumours in primary non-muscle invasive bladder cancer patients.

Published
2014

141. TGFB1 and TGFBR1 polymorphic variants in relationship to bladder cancer risk and prognosis

Author

Castillejo A, Rothman N, Murta-Nascimento C, Malats N, García-Closas M, Gómez-Martínez A, Lloreta J, Tardón A, Serra C, García-Closas R, Chanock S, Silverman DT, Dosemeci M, Kogevinas M, Carrato A, Soto JL, and Real FX

Abstract

The transforming growth factor-beta (TGF-beta) signalling pathway plays an important role in tumor development and progression. We aimed at analyzing whether 7 different common variants in genes coding for 2 key members of the TGF-beta signalling pathway (TGFB1 and TGFBR1) are associated with bladder cancer risk and prognosis. A total of 1,157 cases with urothelial cell carcinoma of the bladder and 1,157 matched controls where genotyped for 3 single nucleotide polymorphisms (SNPs) in TGFB1 (rs1982073, rs1800472, rs1800471) and an additional 3 SNPs and 1 indel polymorphism in TGFBR1 (rs868, rs928180, rs334358 and rs11466445, respectively). In the case-control study, we estimated odds ratios and 95% confidence intervals for each individual genetic variant using unconditional logistic regression adjusting for age, gender, study area and smoking status. Survival analysis was performed using the Kaplan-Meier method and Cox models. The endpoints of interest were tumor relapse, progression and death from bladder cancer. All the SNPs analyzed showed a similar distribution among cases and controls. The distribution of the TGFBR1*6A allele (rs11466445) was also similar among cases and controls, indicating no association with bladder cancer risk. Similarly, none of the haplotypes was significantly associated with bladder cancer risk. Among patients with muscle-invasive tumors, we found a significant association between TGFBR1-rs868 and disease-specific mortality with an allele dosage effect (p-trend=0.003). In conclusion, the genetic variants analyzed were not associated with an increased risk of bladder cancer. The association of TGFBR1-rs868 with outcome should be validated in independent patient series.

Published
2009

142. 2nd combined working group and management committee meeting of urine and kidney proteomics COST action 29-30 March 2009, Nafplio, Greece

Author

Vlahou, Antonia, Allmaier, G., Attwood, T., Bongcam-Rudloff, E., Charonis, Aristidis S., Frokiaer, J., Mischak, H., Schanstra, J., Spasovski, G., Aasberg, A., Allory, Y., Arthur, J., Banks, R., Baumann, M., Benigni, A., Bezerianos, Anastasios, Campistol, J. M., Candiano, G., Capasso, G., Carpentier, S., Dadlez, M., Constantinou-Deltas, Constantinos D., Dijilianov, D., De Zeeuw, D., Decramer, S., Dihazi, H., Domon, B., Endlich, N., d'Alche-Buc, F., D'Haese, P., Edelman, A., Egido, J., El Nahas, M., Farinazzo, A., Fernandez-Llama, P., Feldt-Rasmussen, B., Gansevoort, R., Garbis, S., Garin, J., Ghiggeri, G. M., Gimenez, I., Granier, C., Goumenos, Dimitrios S., Haylor, J. L., Hilario, M., Holthofer, H., Kalousis, Alexandros, Kaski, S., Knepper, M., Korneti, P., Kossida, Sophia A., Langham, R., Loftheim, H., Lopez-Novoa, J., Luider, T., Magni, F., Malats, N., Martin, J. L., Mayrhofer, C., Monsarrat, B., Mueller, G., Nielsen, S., Norling, M., O'Connell, S., Ortiz, A., Perunicic-Pekovic, G., Planelles, G., Polenakovic, M., Promponas, Vasilis J., Rasic-Milutinovic, Z., Rehulka, P., Peter, K., Righetti, P. G., Ronco, P., Ryan, M., Sánchez-Carbayo, M., Semmes, J., Sheehan, D., Stenman, U. -H, Stodkilde-Jorgensen, L., Tasic, V., Theodorescu, D., Thongboonkerd, V., Toncheva, D., Tsillibari, E., Tsiotis, Georgios, Unwin, R., Vanholder, R., Vassilev, D., Vickers, M. E., Verhulst, A., Vilasi, Annalisa, Vlahakos, D., Vonk, R., Wright, P. C., Yamamoto, Tadashi, Yutaka, Y., Zielenkiewicz, P., Promponas, Vasilis J. [0000-0003-3352-4831], and Constantinou-Deltas, Constantinos D. [0000-0001-5549-9169]

Subjects
tumor necrosis factor related apoptosis inducing ligand, medicine.medical_specialty, hypertension, microalbuminuria, urinalysis, heat shock protein 27, laser capture microdissection, Clinical Biochemistry, prevalence, capillary electrophoresis, Clinical proteomics, Urine, Proteomics, Bioinformatics, medical research, disease marker, proteomics, Medicine, Medical physics, Cost action, human, Biomarker discovery, conference paper, mass spectrometry, Kidney diseases, business.industry, lymphocyte antigen, Ontology, practice guideline, bioinformatics, chronic kidney failure, tumor necrosis factor like weak inducer of apoptosis, Laser capture, biological marker, molecular imaging, time of flight mass spectrometry, unclassified drug, Important research, priority journal, Tissue proteomics, Urine specimen, Imaging MS, atherosclerosis, business, Working group, CD74 antigen, monocyte chemotactic protein 1, chronic kidney disease
Abstract

EuroKUP (Urine and Kidney Proteomics www.eurokup.org) is a COST (European Cooperation in the field of Scientific and Technical research: www.cost.esf.org Action fostering amulti-disciplinary network of investigators from 25 countries and focusing on facilitating translational proteomic research in kidney diseases. Four Working Groups focusing respectively on defining clinically important research questions in kidney diseases, kidney tissue proteomics, urine proteomics and bioinformatics have been generated. The EuroKUP members had their second combined Working Group and Management Committee (MC) meeting in Nafplio, Greece from March 29 to 30, 2009. This report summarizes the main presentations, discussions and agreed action points during this meeting. These refer to the design of collaborative projects and clinical center networks for specific kidney diseases establishment of guidelines for kidney tissue proteomics analysis by laser-based imaging- and laser capture microdissection-MS development and characterization of a "standard" urine specimen to be used for assessment of platform capability and data comparability in clinical proteomics applications definition of statistical requirements in biomarker discovery studies and development of a specialized kidney and urine ontology. Various training activities are planned involving training schools on laser capture microdissection- and imaging-MS, workshops on ontologies as well as short-term travel grants for junior investigators. © 2009 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim. 3 1017 1022 Cited By :8

Published
2009

143. 664 - Recurrence and progression according to stage at re-TUR in t1g3 bladder cancer patients treated with BCG: Not as bad as previously thought

Author

Palou, J., Gontero, P., Pisano, F., Joniau, S., Oderda, M., Serretta, V., Larrè, S., Di Stasi, S., Van Rhijn, B., Witjes, A.J., Grotenhuis, A.J., Colombo, R., Briganti, A., Babjuk, M., Soukup, V., Malmstrom, P.U., Irani, J., Malats, N., Baniel, J., Mano, R., Cai, T., Cha, E.K., Ardelt, P., Varkarakis, J., Bartoletti, R., Dalbagni, G., Shariat, S., Xylinas, E., Karnes, R.J., and Sylvester, R.

Published
2017
Full Text
View/download PDF

144. 380 - Prognostic impact of a 12-gene progression score in non-muscle invasive bladder cancer: A prospective multicenter validation study

Author

Dyrskjøt, L., Reinert, T., Algaba, F., Christensen, E., Nieboer, D., Hermann, G., Morgensen, K., Marquez, M., Segersten, U., Hoyer, S., Ulhøj, B., Hartmann, A., Stöhr, R., Wach, S., Nawroth, R., Beukers, W., Schwamborn, K., Tulic, C., Simic, T., Junker, K., Harving, N., Petersen, A.C., Jensen, J.B., Keck, B., Horstmann, M., Maurer, T., Steyerberg, E., Zwarthoff, E., Real, F., Malats, N., Malmström, P.-U., and Ørntoft, T.F.

Published
2017
Full Text
View/download PDF

145. EphB activity suppresses colorectal cancer progression

Author

Batlle, E., Bacani, J., Begthel, H.L., Jonkheer, S., Gregorieff, A., van den Born, M.M.W., Malats, N., Sancho, E., Boon, E., Pawson, T., Gallinger, S., Pals, S., Clevers, J.C., and Hubrecht Institute for Developmental Biology and Stem Cell Research

Published
2005

147. INBIOMED: plataforma de almacenamiento, integración y análisis de datos clínicos, genéticos, epidemiológicos e imágenes orientada a la investigación sobre patologías

Author

Martín-Sánchez, Fernando, Bueno, G., Coltell, O., Corella, D., Díaz, J., Heredia, J. A., López, V., Loza, Maria A., Malats, N., Maojo Garcia, Victor Manuel, Pastor, X., Pazos, A., Robles, M., and Sanz, F.

Subjects
Informática, Medicina, Biología
Abstract

INBIOMED es una Red Temática de Investigación Cooperativa Sanitaria en Informática Biomédica, financiada por el FIS-ISCIII, e integrada por trece grupos españoles pertenecientes a las áreas de bioinformática, informática médica-clínica, procesado de imágenes, epidemiología y farmacogenómica. Uno de los principales objetivos que pretende la Red INBIOMED es definir y desarrollar una infraestructura informática distribuida para almacenar y relacionar todos los tipos de datos relevantes para la investigación clínica, epidemiológica y genómica de enfermedades complejas (cáncer, cardiovasculares, psiquiátricas, neurodegenerativas, etc.), estructura que estará fundamentada en el conocimiento de los estándares existentes. INBIOMED pretende además definir, desarrollar e integrar herramientas de análisis que permitan procesar, modelizar, visualizar y predecir conocimiento biomédico. Los sistemas y modelos que se desarrollen en esta Red Temática podrán estar disponibles para ser utilizados por otras redes de patologías, lo que supondrá un reto de investigación para el desarrollo de nuevas tecnologías que posibiliten el abordaje de enfermedades complejas.

Published
2004

148. Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33

Author

Wang, Z., primary, Zhu, B., additional, Zhang, M., additional, Parikh, H., additional, Jia, J., additional, Chung, C. C., additional, Sampson, J. N., additional, Hoskins, J. W., additional, Hutchinson, A., additional, Burdette, L., additional, Ibrahim, A., additional, Hautman, C., additional, Raj, P. S., additional, Abnet, C. C., additional, Adjei, A. A., additional, Ahlbom, A., additional, Albanes, D., additional, Allen, N. E., additional, Ambrosone, C. B., additional, Aldrich, M., additional, Amiano, P., additional, Amos, C., additional, Andersson, U., additional, Andriole, G., additional, Andrulis, I. L., additional, Arici, C., additional, Arslan, A. A., additional, Austin, M. A., additional, Baris, D., additional, Barkauskas, D. A., additional, Bassig, B. A., additional, Beane Freeman, L. E., additional, Berg, C. D., additional, Berndt, S. I., additional, Bertazzi, P. A., additional, Biritwum, R. B., additional, Black, A., additional, Blot, W., additional, Boeing, H., additional, Boffetta, P., additional, Bolton, K., additional, Boutron-Ruault, M.-C., additional, Bracci, P. M., additional, Brennan, P., additional, Brinton, L. A., additional, Brotzman, M., additional, Bueno-de-Mesquita, H. B., additional, Buring, J. E., additional, Butler, M. A., additional, Cai, Q., additional, Cancel-Tassin, G., additional, Canzian, F., additional, Cao, G., additional, Caporaso, N. E., additional, Carrato, A., additional, Carreon, T., additional, Carta, A., additional, Chang, G.-C., additional, Chang, I.-S., additional, Chang-Claude, J., additional, Che, X., additional, Chen, C.-J., additional, Chen, C.-Y., additional, Chen, C.-H., additional, Chen, C., additional, Chen, K.-Y., additional, Chen, Y.-M., additional, Chokkalingam, A. P., additional, Chu, L. W., additional, Clavel-Chapelon, F., additional, Colditz, G. A., additional, Colt, J. S., additional, Conti, D., additional, Cook, M. B., additional, Cortessis, V. K., additional, Crawford, E. D., additional, Cussenot, O., additional, Davis, F. G., additional, De Vivo, I., additional, Deng, X., additional, Ding, T., additional, Dinney, C. P., additional, Di Stefano, A. L., additional, Diver, W. R., additional, Duell, E. J., additional, Elena, J. W., additional, Fan, J.-H., additional, Feigelson, H. S., additional, Feychting, M., additional, Figueroa, J. D., additional, Flanagan, A. M., additional, Fraumeni, J. F., additional, Freedman, N. D., additional, Fridley, B. L., additional, Fuchs, C. S., additional, Gago-Dominguez, M., additional, Gallinger, S., additional, Gao, Y.-T., additional, Gapstur, S. M., additional, Garcia-Closas, M., additional, Garcia-Closas, R., additional, Gastier-Foster, J. M., additional, Gaziano, J. M., additional, Gerhard, D. S., additional, Giffen, C. A., additional, Giles, G. G., additional, Gillanders, E. M., additional, Giovannucci, E. L., additional, Goggins, M., additional, Gokgoz, N., additional, Goldstein, A. M., additional, Gonzalez, C., additional, Gorlick, R., additional, Greene, M. H., additional, Gross, M., additional, Grossman, H. B., additional, Grubb, R., additional, Gu, J., additional, Guan, P., additional, Haiman, C. A., additional, Hallmans, G., additional, Hankinson, S. E., additional, Harris, C. C., additional, Hartge, P., additional, Hattinger, C., additional, Hayes, R. B., additional, He, Q., additional, Helman, L., additional, Henderson, B. E., additional, Henriksson, R., additional, Hoffman-Bolton, J., additional, Hohensee, C., additional, Holly, E. A., additional, Hong, Y.-C., additional, Hoover, R. N., additional, Hosgood, H. D., additional, Hsiao, C.-F., additional, Hsing, A. W., additional, Hsiung, C. A., additional, Hu, N., additional, Hu, W., additional, Hu, Z., additional, Huang, M.-S., additional, Hunter, D. J., additional, Inskip, P. D., additional, Ito, H., additional, Jacobs, E. J., additional, Jacobs, K. B., additional, Jenab, M., additional, Ji, B.-T., additional, Johansen, C., additional, Johansson, M., additional, Johnson, A., additional, Kaaks, R., additional, Kamat, A. M., additional, Kamineni, A., additional, Karagas, M., additional, Khanna, C., additional, Khaw, K.-T., additional, Kim, C., additional, Kim, I.-S., additional, Kim, J. H., additional, Kim, Y. H., additional, Kim, Y.-C., additional, Kim, Y. T., additional, Kang, C. H., additional, Jung, Y. J., additional, Kitahara, C. M., additional, Klein, A. P., additional, Klein, R., additional, Kogevinas, M., additional, Koh, W.-P., additional, Kohno, T., additional, Kolonel, L. N., additional, Kooperberg, C., additional, Kratz, C. P., additional, Krogh, V., additional, Kunitoh, H., additional, Kurtz, R. C., additional, Kurucu, N., additional, Lan, Q., additional, Lathrop, M., additional, Lau, C. C., additional, Lecanda, F., additional, Lee, K.-M., additional, Lee, M. P., additional, Le Marchand, L., additional, Lerner, S. P., additional, Li, D., additional, Liao, L. M., additional, Lim, W.-Y., additional, Lin, D., additional, Lin, J., additional, Lindstrom, S., additional, Linet, M. S., additional, Lissowska, J., additional, Liu, J., additional, Ljungberg, B., additional, Lloreta, J., additional, Lu, D., additional, Ma, J., additional, Malats, N., additional, Mannisto, S., additional, Marina, N., additional, Mastrangelo, G., additional, Matsuo, K., additional, McGlynn, K. A., additional, McKean-Cowdin, R., additional, McNeill, L. H., additional, McWilliams, R. R., additional, Melin, B. S., additional, Meltzer, P. S., additional, Mensah, J. E., additional, Miao, X., additional, Michaud, D. S., additional, Mondul, A. M., additional, Moore, L. E., additional, Muir, K., additional, Niwa, S., additional, Olson, S. H., additional, Orr, N., additional, Panico, S., additional, Park, J. Y., additional, Patel, A. V., additional, Patino-Garcia, A., additional, Pavanello, S., additional, Peeters, P. H. M., additional, Peplonska, B., additional, Peters, U., additional, Petersen, G. M., additional, Picci, P., additional, Pike, M. C., additional, Porru, S., additional, Prescott, J., additional, Pu, X., additional, Purdue, M. P., additional, Qiao, Y.-L., additional, Rajaraman, P., additional, Riboli, E., additional, Risch, H. A., additional, Rodabough, R. J., additional, Rothman, N., additional, Ruder, A. M., additional, Ryu, J.-S., additional, Sanson, M., additional, Schned, A., additional, Schumacher, F. R., additional, Schwartz, A. G., additional, Schwartz, K. L., additional, Schwenn, M., additional, Scotlandi, K., additional, Seow, A., additional, Serra, C., additional, Serra, M., additional, Sesso, H. D., additional, Severi, G., additional, Shen, H., additional, Shen, M., additional, Shete, S., additional, Shiraishi, K., additional, Shu, X.-O., additional, Siddiq, A., additional, Sierrasesumaga, L., additional, Sierri, S., additional, Loon Sihoe, A. D., additional, Silverman, D. T., additional, Simon, M., additional, Southey, M. C., additional, Spector, L., additional, Spitz, M., additional, Stampfer, M., additional, Stattin, P., additional, Stern, M. C., additional, Stevens, V. L., additional, Stolzenberg-Solomon, R. Z., additional, Stram, D. O., additional, Strom, S. S., additional, Su, W.-C., additional, Sund, M., additional, Sung, S. W., additional, Swerdlow, A., additional, Tan, W., additional, Tanaka, H., additional, Tang, W., additional, Tang, Z.-Z., additional, Tardon, A., additional, Tay, E., additional, Taylor, P. R., additional, Tettey, Y., additional, Thomas, D. M., additional, Tirabosco, R., additional, Tjonneland, A., additional, Tobias, G. S., additional, Toro, J. R., additional, Travis, R. C., additional, Trichopoulos, D., additional, Troisi, R., additional, Truelove, A., additional, Tsai, Y.-H., additional, Tucker, M. A., additional, Tumino, R., additional, Van Den Berg, D., additional, Van Den Eeden, S. K., additional, Vermeulen, R., additional, Vineis, P., additional, Visvanathan, K., additional, Vogel, U., additional, Wang, C., additional, Wang, J., additional, Wang, S. S., additional, Weiderpass, E., additional, Weinstein, S. J., additional, Wentzensen, N., additional, Wheeler, W., additional, White, E., additional, Wiencke, J. K., additional, Wolk, A., additional, Wolpin, B. M., additional, Wong, M. P., additional, Wrensch, M., additional, Wu, C., additional, Wu, T., additional, Wu, X., additional, Wu, Y.-L., additional, Wunder, J. S., additional, Xiang, Y.-B., additional, Xu, J., additional, Yang, H. P., additional, Yang, P.-C., additional, Yatabe, Y., additional, Ye, Y., additional, Yeboah, E. D., additional, Yin, Z., additional, Ying, C., additional, Yu, C.-J., additional, Yu, K., additional, Yuan, J.-M., additional, Zanetti, K. A., additional, Zeleniuch-Jacquotte, A., additional, Zheng, W., additional, Zhou, B., additional, Mirabello, L., additional, Savage, S. A., additional, Kraft, P., additional, Chanock, S. J., additional, Yeager, M., additional, Landi, M. T., additional, Shi, J., additional, Chatterjee, N., additional, and Amundadottir, L. T., additional

Published
2014
Full Text
View/download PDF

149. 1001 The impact of re-TUR on clinical outcomes in a large cohort of t1g3 patients treated with BCG

Author

Gontero, P., primary, Sylvester, R., additional, Pisano, F., additional, Joniau, S., additional, Vander Eeckt, K., additional, Serretta, V., additional, Larrè, S., additional, Di Stasi, S., additional, Van Rhijn, B., additional, Witjes, A., additional, Grotenhuis, A., additional, Kiemeney, B., additional, Colombo, R., additional, Briganti, A., additional, Babjuk, M., additional, Soukup, V., additional, Malmström, P.U., additional, Irani, J., additional, Malats, N., additional, Baniel, J., additional, Mano, R., additional, Cai, T., additional, Cha, E., additional, Ardelt, P., additional, Varkarakis, J., additional, Bartoletti, R., additional, Sphan, M., additional, Dalbagni, G., additional, Shariat, S., additional, Xylinas, E., additional, Karnes, J., additional, and Palou, J., additional

Published
2014
Full Text
View/download PDF

150. Genome-wide interaction study of smoking and bladder cancer risk

Author

Figueroa, J. D., primary, Han, S. S., additional, Garcia-Closas, M., additional, Baris, D., additional, Jacobs, E. J., additional, Kogevinas, M., additional, Schwenn, M., additional, Malats, N., additional, Johnson, A., additional, Purdue, M. P., additional, Caporaso, N., additional, Landi, M. T., additional, Prokunina-Olsson, L., additional, Wang, Z., additional, Hutchinson, A., additional, Burdette, L., additional, Wheeler, W., additional, Vineis, P., additional, Siddiq, A., additional, Cortessis, V. K., additional, Kooperberg, C., additional, Cussenot, O., additional, Benhamou, S., additional, Prescott, J., additional, Porru, S., additional, Bueno-de-Mesquita, H. B., additional, Trichopoulos, D., additional, Ljungberg, B., additional, Clavel-Chapelon, F., additional, Weiderpass, E., additional, Krogh, V., additional, Dorronsoro, M., additional, Travis, R., additional, Tjonneland, A., additional, Brenan, P., additional, Chang-Claude, J., additional, Riboli, E., additional, Conti, D., additional, Gago-Dominguez, M., additional, Stern, M. C., additional, Pike, M. C., additional, Van Den Berg, D., additional, Yuan, J.-M., additional, Hohensee, C., additional, Rodabough, R., additional, Cancel-Tassin, G., additional, Roupret, M., additional, Comperat, E., additional, Chen, C., additional, De Vivo, I., additional, Giovannucci, E., additional, Hunter, D. J., additional, Kraft, P., additional, Lindstrom, S., additional, Carta, A., additional, Pavanello, S., additional, Arici, C., additional, Mastrangelo, G., additional, Karagas, M. R., additional, Schned, A., additional, Armenti, K. R., additional, Hosain, G. M. M., additional, Haiman, C. A., additional, Fraumeni, J. F., additional, Chanock, S. J., additional, Chatterjee, N., additional, Rothman, N., additional, and Silverman, D. T., additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results